var title_f12_60_13248="Myeloma kidney-immunofluorescence microscopy";
var content_f12_60_13248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myeloma kidney-immunofluorescence microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy with anti-human lambda antiserum showing variable staining of intratubular immunoglobulin light chain casts from a patient with multiple myeloma excreting monoclonal lambda light chains. The weaker staining casts presumably contain more Tamm-Horsfall mucoprotein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13248=[""].join("\n");
var outline_f12_60_13248=null;
var title_f12_60_13249="Hepatitis A virus and recombinant hepatitis B virus vaccine: Patient drug information";
var content_f12_60_13249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hepatitis A virus and recombinant hepatitis B virus vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/39/43637?source=see_link\">",
"     see \"Hepatitis A virus and recombinant hepatitis B virus vaccine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Twinrix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Twinrix&reg;;",
"     </li>",
"     <li>",
"      Twinrix&reg; Junior",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10026001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_hepatitis_a.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS) - Hepatitis A",
"       </a>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705992",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_hepatitis_b.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS) - Hepatitis B",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11762 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13249=[""].join("\n");
var outline_f12_60_13249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178886\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178887\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026001\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/39/43637?source=related_link\">",
"      Hepatitis A virus and recombinant hepatitis B virus vaccine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_60_13250="Diagram colon rectum PI";
var content_f12_60_13250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Diagram of the colon and rectum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 561px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIxAcsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkLKOpA/Gl71geMjNFpYubdyrQsCcdx0qKk+SLl2Lpw9pNR7m75if31/OgOp6Mv5151Y6xMy/M5P1rUg1WQ45rljjYvodUsFKJ2W4eo/OlyPWubg1FyauJek9TWqxEWYuhJGxRVBLsEdad9pHrV+1iR7Nl3NGapfah60n2oetHtYh7Nl7NGao/ah60fah60e1iHs2Xs0VR+1j1oF0PWj2sQ9my9RVMXI9aPtIp+1iL2bLlFVPtI9aT7SKPaRD2bLlFU/tQ9aT7UPWj2sQ9my7mjNUTdgd6ia/Ud6Xtoj9lI08ijI9RWct6rDg077UKPbRD2bL+aKordD1p4uV9aftIi9my3RVb7QtIblfWn7RByMtUZqkboetNN2PWp9rEfs2X80Zqh9rHrR9qHrR7aIezZfzRms83Y9aQ3gpe2iHsmaOaMj1rN+2D1o+1j1o9vEfspGlketGR61m/ax60fbB60e3iHsmaWR60ZrN+2Cl+2D1o9tEPZM0cj1oyPUVkvfhe9QyamApxUvERQ1Qkzb3L/eH50ZB6EVx1xqjruZWrGn8Q3fmYRyMVg8dFdDojgZy2Z6XRVDQZpbjSbaafmR1yav12xlzJS7nHKPK3HsFFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAd6q6nbrd2M0D/ddSDVqg80mrqzGm07o8YjLW87xPwyMVP1FadtOc9ab4zszY69KQMJNh1Pqe9U7aTpXz0ounJx7H0t1UgprqdFBcVaSc1iwvVtHqlJnNKCNdJ2HQ0/7Scdaz43qbOarnZk4Is/aD60v2g+tVc0U+di5UWvtBpPPPrVaijnYcqLPnn1pRcH1qtRS52HKi0Lg+tL9oPrVWinzsXIi19pPrSG5PrVWijnY+RFg3BpPtDVXNNzS52CiieS4bHWqc10w705zxVG4NJzZpGCNK0umbjNaCyErWDp7fOK3E+6K0hJszqRSYhmK96PtLCmSDmoWFDk0Sopln7U1I10x71VoqfaSK5ET/AGhqPPb1qCilzMOVE3nt60ee1Q0UczHyom89qPOaoaKOZhyom840nnNUVBpczDlRJ5xpfONVyaUGjmYcqJ/ONBmOKgLVG7UczGooleYnvVS4nOCAaSV8Cs66lxmpcmawgMubjCkZqhBGbm6jjX7zsFH41HdSk1teA7Q3WsLIwykI3n69qmEXUmo9zeTVKDl2PSraJYLeKJBhUUKKkoor6NK2h803fUKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOT+IWnG50v7Sg+eA5/Dv/AJ9q8+tpOBXtNxClxA8UgyrggivE72JrDUZ7Zusblfw7V5WPp2kprqe1l1Tng6b6GrbycDNX43zWDBNmtKCXiuBHVOJqI9WkYGs1HqeOTBq0zFxL4oNRI4IqCe72HC8mi5Ci2W6cKyzeyZ7VPb3m47ZOKLobpsvA0uaQUUyBaSiigAoozSZoADUbU8mozyaBoY/SqVznBq6/AqpPg5qWaRF00fPmt5D8grFsBitiI/LWtNmVXcVxmomFTnpTGFW0Zplc0madIMVFmsmaIfmim5ozSAeBRimg0uaYhaSioLm4EK+9IaVyeg1jS6pJnCKMetJFqjlsPip5kaeyka7VGWxTLecTj3ok707iSs7MC9MLcZNRlsVBLLgdam5aiJcTYrIuZ8k81NdTcGsuV+TUtm8Ig7bmr0vwDYG10kzuPnuDuH+6OleaWMZub2CEceZIqfmcV7dbxJBBHFGMIihR9BXdl9Pmm5voceZVOWCgupJRRRXrnihRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L8R7b7P4gMijAlQN+PevWq4T4o2m+C0uQOVYofxH/1q5MbHmpN9juy+fLXS7nnkExB61qWs3A5rDcFGqxbzkd68U96UTp4ZcirCSVi29x05q6kwNO5hKBqiQeUTVB5fmanRzAjB6GmSQ7uVNDIiktwa5g8khzhsc1FZysV+fPtThbluoH5VZt7UBuTQXdJGraMTGuT0qfNVkYKuBTvM96tHK1dk5NJuFQGQU3zaLhylgmm7qhMlIHouFiYnNGcCo9/FRvJQNIdI1U5m5xUkj5HFQdWpM0ii5a5GK1IWxWfAuEBqzG1VF2Mpq5bzS9qgDUu6tOYysJJVdqkkaoWNRJmkUGaN1RlqaWqCrE4anBqqhzS+YcU7hyloNWbqBO8+lWBLg9aZMBKKT1KiuVmM77HUlSyjqKZdTLcNGIEwwPJxir8loSc02O1IPOBUam/NHcl08nzeOnersr4zVeMrCpx1qGabOarZGTXM7iySYqlPN6Uk03vVKaUDrU3NYxI7mSqDSZPWnXMuarKCxzUm8UbvhSPzfEOnr/02Dflz/SvZq8n+H8XmeJbckcIjv8Apj+tesV6+XL9235ni5o/3qXkFFFFegeaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWD42txceHbrIyYwHH4Gt6q2pQC50+4hPSSNl/SoqR5oOPc0pS5JqXZnhc0fNVcFDxWpPEVzkcjrVZo92fWvm0z6zcZDMR3q7FceprNkjKmmrIVp7kuJvJce4qzHcVziz1ZjuPeghwOjjnHrUomGOtYEdz71aS5GOtO5k4GyJ/el873rJW4FSCf3p3J5DSMp9aBL71nib3oM3vRcOQ0xIDTwwxWUs5p/wBp96dyXAvtL2zUTyZqkZ80CQk8UXBRsW1OanhQE81Wh3HtVtOBzQJlpTxgU8GoEJNTgVRkyVTxS7sCmYpjhqdybBI3FQM9DlgDmq7PjrUtlpDzJTDJUTvURkFTctIsF/ejf71W35700v70XHYtb/egSVSMuB1pjTUrlcpomX3qN5lHfNZ7Te9RPMaLjUC5LcVVlnJqszMxpAjGlctRSEklqs7E1OYyaYybRSNFZFRoyx5pQm2pHYL0pAdxFBSO0+GUGdRvJiPuRBQfqf8A61ei1x/w0t9mmXU5H+tlwPoo/wDrmuwr3cFHloo+ex8uavLyCiiiuo4wooooAKKKKACiiigAooooAKKKKACiiigAooooAKRuhpaD0oA8g1yDyNTu4sfdlb8s5rKCfPXU+OIfK16RgOJUV/0wf5Vz2ATXzlWPLOUfM+ooz5qcZd0QSRAjpVV7U9q1gmV6U5Yh3rOxrz2RhG1fPSlEDj1ro1t1I6Cg2antVWI9oc8EYU8Fh61uGyU9qFsF9KYnNGRGWqzHurTWwX0qVbMDtTsQ6iM5VbFPCt6VpLbCpVth6UWI9oZYjY9qd5DnoK10tx6VOkIHajlJdQx47N2q3BYkHJrURAB0p+2q5SHUZTWEIOBRtqy68VXfg0mJO45GAqdORVMHmrkP3RQgloSgUYooqjMYyAjpVOaAHOKv4pjClYpOxjvCQTUDRHPStl0GelQtGPSlY0U2ZXlsO1Rurela+welIYl9KXKUqhikN6U0ox7VsmFfSm+QvpS5SvaIyBEfSnCAmtTyRR5aiiw/aGWYMdqawAFaUyqBVCbaBRYalcrOwAqlPNngU+4LMxC9KjS3OcmpZtFdWVjktU0YpzoA3HQU6JS7BR1Y4FSWmet+DoPs/hyyUjBdfMP4nNbVRWkQgtYYgMCNAv5Cpa+lpx5YqPY+UqS55uXcKKKKsgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDh/iJD81nN/vIf0P+NcWa9E8fQl9JWQf8spQfwIxXAbM9K8HHR5az8z6LASvQXkTW/zKKnMfcCoLUbW5rSRQRXKmbyKy5BqZD7VN5INOWDnpWq1MJMYBntT1T2qdIamWGnYhyKwT2p2yrgjpfLFOxHOUwh9KlSOrAQVIqU1ETkQLH7VIsdThakVatRM3IgEdO2YqfFBHFUok8xTkXiqcg5rQlFVJF5rOSNYMqEfNV6H7tVHHzCrcP3aziXLYkoooqzMKQ07FJQBGw5phWpqQigdyuVpNvtVgik20rD5iuVPpSFasEe1RspNFhplZhULqe1XDH601kAFKxSkZcyuRVZoT3rVlUVVkwDSZpFlHyQDyKjlwmasuw5zVGfLtxWVzoiVX+ZjWh4ftjcaxYxYzumXP0Byf5VXSIAc10fgS383X1fHEMbP+J4H860ox56kV5k1p8lOT8j0qiiivpD5cKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAy/E0H2jRbxO/llh9Rz/SvL4mFewzIJI2RujAqfxrxyZDDPJGeCjFT+BrycyjaUZHs5ZK8ZRLsSgnir0K4rNs5PnANbEODXnbndK6HqnpUi/SnItPK1okc0mOUDFPAqIEinhsiquZtD6XFNWniqJYoFPUUgFSKKtIlsQCpUHFMxUi1aRDAjFGOKdRjg1diStIKqSjmrsgqpLWM0bQM+U/PVy3OVFU5vv1btPuVjHc3nsTUopQKcBVmI3FIRUuKaRTsK5HRilIpKkoTFFLRQAlNp9NZqBjSKrykDvUjse1VZskmpbLiivPIOcVRlcmrMimoSgFQ9TeNkVSDjmo8DOasOvaqrnsKlmqCRvSu0+G8H7u9uCOSVjB+gyf51xQXNeleB7fyNAiYjmVmf8AXH9K68BHmrX7HLmEuWg13Ogooor3DwAooooAKKKKACiiigAooooAKKKKACiiigDhfi14yu/Bdj4durOCKZL/AFu20+4DwyTMIZN5cxoh3F/l4ADZ9DXJ2fxus7XVfFn9vxGDTdPv7Wx05Ps7WtxM0qMxEouGQJjYTltgA69q9F8cWPh+fSYdQ8VqgsNGuE1RJXkdBDLFkq/ykFsZPynIOehrlNL0/wCHfi3V9Xhs7WeTVL77Pq12JUu7WYFdywzKX2mNvvYKbTg56EGgCOy+NWgajFpB0nTtX1C41NrtIre3WAsjWyh5FZjKEPysCCrMD2PSm6v8b/DOmeH9L1yWC9k0zULcXEbrLarIBvKMvkvMsrFWHOxWHoTzV3xB8KtP1jXvDl2+o6mtjpIuxJbyX1zLNcCeNUIFwZfMQDb0BIIJHAJzbvPhN4Ju4lifRBFELRbAx211NAskAO4I4RwH55y2TnnNAHGzfF/UorTx9dXOnfZrDQLqGK2vEtUuAUd41AeP7SjMzB9wIKgDryNp9B0fxtb634h1DS9H0rU7yHTro2V3qCCFbeGZRlk+aQOxHAO1DyRUF78M/Cd6uqpcaZIYtUSNL2JLydI5vLKFGKK4XcCi/MBu688nOjbeDtFtPENxrVnBc2t/cSedP9nvZ4opnxjdJCriNzjuymgDoG6V5b4ot/I1+7UDAZt4/EZr1M9K888ex7daifGA8I/QmuDMI3pJ9mehlsrVWu6MKFcMCK1rZ8YzWXCelaUI6V41j2JO5ooamFVY+gqZWxW0TkkiQrSAUobNLVGYCnCm04U0Jkq1ItRrUq9K0iQxaetJigGtEQxwpe1MJ5pc8U7iIpKqTVZkqtLWMzWBn3H36tWn3Kq3H36tWn3Kxjuby+EtKKeBTVp69q1RgxcU1hTxTWqmJETCmmntTDWbLQlFFFIYhppFPpCKAImFV5R1q23FVZ2AzSZSZSm4FVWNSXEtUy5JqWbwQ6Q8Gqh5NWJPu1BWR0IM7R9K9a0KLyNGsoz1WFc/lXjGpapYaYIm1K6it0kcIoY5ZyT0VRyx9gCa9BTWfEmtosfh3SBpVkRgahrKFWIx1jtVIc/9tGj+hr08ujrKR5mZyVoxLnxJ1rWdA8JXWoeG9JfVdSRkVIEjaQgFgGfYuGfA52rgn2rifD/xjs5be3ju2bWL66vk0+GHTrFrOVJWQuFliuJMJ0wCJGB9u3a+JLfS7LwY8vjbUXns7EefPfsxt3VgThl8naVI3YG3np1PNcD/AMIf4N8X6pZWXhy+v7G70q+h1nUFmjvEvLgOjKm6eVllUkA4O4lR2Ga9U8gWb4tQXninwxeWl1cWPhyS01STU7e5gTzEe2VeGI3HK8/cYg5HWrNv8f8AwlPZXdxHBqTtbrBJ5MfkSO6SuEVhslIGCw3KxVhnla6+y+HHhKySwS20aFUsobiCFWkdhsnGJg4LHeWHUvk+9Rt8NPC76X/Zktrfzab+722s2q3ckUflsGTYjSkJggfdA446cUAYlz8VLOaW0htoLywul8RQaDd293ZpK4eQEjBScKoOPvgvj+4c10Xgzxtb+MN1xo2lam2j75Ei1SUQrBMUbadi+Z5hGQQCUA4NOl8AeGZb6S8fTc3Empx6wz+fLzdxghJMbscAn5funuKsaB4O0Xw/fTXWiwXNp5zO7W8d7P8AZtznLMIC/lKSe4UUAdDRRRQAUUUUAFFFFABRRRQBw/xs8P3/AIo+GGuaTo8Mk+ozxr5EST+TvYODgksoIxnhjg15zr3gPxva6h4hn8IedaSzaNYWlvcyXoeWRo3zLGHZy4bGQGJA7AjqPfqKAPn648M/Es+HRbaReeIYtXOpefb3F7eRxxWcJT50cfa7hpkJxtDFipyeB1l1PQ/iPHY2J0u28Q/vfDE9hLDJrcbywaiWJWZ3aYBs9nUkgEDC4xXvlFAHhlj4N+Id5qLXFzrut6c9r4ftFtB/aSvBLqKwFZPOTLFhvOSejHnLVtfBjRfGmlalcyeLrvV3jks0R4bt0mh89SNzxyfa5nyecjZGvTCr0r1migCpqwvjp0/9km2F/tzD9qDGIt6Nt5APTI6dcHofLvFniUTXdhZ69YS6Nq+WjEUzb4Z++YZh8r/Thx3UV65XK/ErTbbVPC80F7bxXMAdS0cqhlIzjofrXPioqVKSZ04STjWi0cNA3Na9tyorz+Cw1fQ33aNKdSsB/wAuF3L+9Qf9Mpj1/wB18/7wrq/DXiCw1dpIIXeG9iGZbO4Xy5ovcoe3uMg9ia8Pk0utUe3Oetnozo46k20xBxU61SMJEQyKkVqcVBpAtURcdSikFKKCWTJUyVAlTpW0TORJ2pjU8V5/8bdQ1XQ/AWo65oerXOn3dgisqRxQyJKWkRfnEiMeATjaR15zWijd2M27andE80gbivNrnxfq2ieJtK8M21hdeIrq6s11Ca9uLuC2aKMybWJVY1UhRzxyenvWUnxjQ3N6g0qG4gj0661C2ubW5lMVwIAdyBpIE/ukbk3gHil7OXQfPHqettVeWvM7f4qahPDdLH4Vnub1dLttVt7eyujMZY5iBg/uwVK552q3Q4qpffGG3sdPtdQvrG2OnzPdQPPbXMreTcQpuELLJBGwZugyBg1LpTfQuNSK6npE336t2v3K8iv/AIpX0OpCxi8KXtzew21vcXdvbmWV4/NAO1NsRDbQeSxQZBAzitCx+I+s3KeIpdP8GXV7aaRczWay292rtPNHIi7RGF3gFWLEgNjGOazVGad7GsqsWrXPV1p4ryKb4w/u9Ph0/R11HUrt7lPItZLllQwgFkP+jeZv5xt8vA4JIHNemeHdRk1fQ7K/msrmwluIg72tyhWSJu6sDg8GrcJRV2jJTUtjTprUuaa1JjRG1NpTTazZaCiiikMKaTTbiaOCIySsFQdzWPPrQ58i3dx6scU0m9jSFKVT4Uasr1RnJOapRayHP76Box6g5q67oYTLvURAbi5PAHrmk00XKlKn8SM+ZCTUOzFZM/imG8dovDdpNrUg4M0BCWyn3nPyn6JuPtVSTRNU1Q58QamUgPWy00tDGfZpf9Y34bB7UnC3xaBGd/h1J9W8SadY3JtFeS71Af8ALnZoZZR9QOEHuxA96zmj8RaocyyRaHan+CLbPcke7HMafgH+tb+n6dZaXbC3061htoc52RIFBPqcdT706U1m5JbI2jFy3YzwF4b0608TWUsEHmXZfdJdTsZZnAGeXbJxx0HHtXtleaeAo9/iBW/uROf5D+tel162X3dNyfc8nMrKoorojz749eG9S8WfCzWNJ0OCS51OUxNBCk4hDkSoWBJZVI27jhjjgdwK4nxP4H8bW2seMrjwcZ7cXdtpsNtPJe75rhIgwmRZGk3h+R8zMpPZh1r3eiu8888CuPDPxJ/4ROK00m98QR63/arzwXN7dxxR2luUG6OQfargzoTwoYsynJ4HJi1PQfiWlig0u38RD7R4X+weU+txvJb6iJt5md2mAJZcgOuSAQMKBgfQVFAHiVn4N8fXevaxe3Gu61p5g0m1XS4/7RV7aW8FqUk82PLEgSck8Ann5q1PgxovjTStSuZPF13q7xyWaI8N26TQ+epG545Ptcz5PORsjXphV6V6zRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZ+vw/aNHu4upaJsfUDP9K0KZMu+Jl9RipkuZNFQlyyTPGYT8wqS+0Ww1pIvtsR8+I7obiJjHNCfVHHI/ke+aZt2zMvoSK0bM/NXzcW1sfTVUmtTMivNd8OjGpRya5pa9Lu2jH2qIf9NIhxJ/vJg/7B610+j6pY6vZLd6ZdRXVuxxvjbOCOoPoR3B5FOhPArI1Xwvb3V4+o6ZcS6TrBAzd2oH7zHQSoflkH+8MjsR1rZNS30OKcXHY6SiuTXxLd6Kwh8Y2qWsecLqltlrR/9/PzQn/eyv8AtnpXUGeEW4nMqeQV3CTd8pB6HNNxaITvoiSisZ/EEG8rbxSSj+9naDQutPjLWh2+z5P8qaizo+rVexuoanQ1lafqUF58sZKyDqj8H/69aCtVJ2OecHF2aLO6qupWVpqdnLaajawXdpKAJIZ4xIj4ORlTweQDUm+kL5q+Yy5Sr/Z9kL9L4Wdt9tSLyFuPKXzFjznYGxkLnnHSs2Dwj4ageV4PD2jxvKrpIyWUQLq4w4OF5DDgg9a2s1xPxH8K3niS50Ke2WxvLbT7hpZ9M1B2W3vAVwN5Ctyp5GVI5OaUXd2uOS02N278LeH7mPZc6FpUyCJIAslnGw8tPuJyPur2HQVgaL/wjOvW+paTaaHapZ6Pfm2a3ltIhEJlAO9FGR/F1wD1rj/EHww1fUr+8mtF0ax+0iz+zTRSv5mjCH76WoEQBVv+2fU5BpNS+G2ry6vd3rNpd/aya1PqJ026kcQXEbxKi+YdjYdSCQNrDnrVtRt8Qot3+E77V/D2jaxcJNq2kadfTINqvc2ySso9AWBxVweHdFnsri0n0jTpbW4mNxNC9sjJJKesjKRgtx94815NH8JNTez0631C60+/S20m7sj55YhJZWLR7MqflTIw3UY4HQV6v4K0260fwnpGnahKs13aWscEsiMWVmVQCQSASOO4rFpR2lc1u5bxsTP4W8PzadFYTaFpUljExaO2azjMaE9SFxgGtWwtLawtIrWxt4ba2iG2OGFAiIPQKOAKcKeDQpMmyH01qUGmtTYDGptKaTp1qGUgqG6uoLSMvcSrGo9TyapareyJKtrakCZhlm/uj/GsS/tIkjIuH8yR+pJyaqMG1c66OG57OTsPe7F9e+ZM37sfdTPAFWJ5UYbIQM/yrBt7G7jmGJAID0DD5vw/+vWjO4tIBkct90HqT6mtouyPQcIqyiRyjnaCSf1P+FVNR8OQ6vDEuoQCeKNt6xOSY8+pXo34g4rR08qf3khyx61rPdKI8DA4qoxT1InL7NrnKvNeaeVVJSY1GAh5AHpitK1u1u4g4GGHDL6VT1WRWLetVNEf/SnUHgjmuapFGk6cZQ5rWaNpqqy9ast3qq/WuWRywOr+HKg6pct3WH+bD/CvQa4T4br/AKVfN6Ig/U13de5gF+5XzPCzB/v38gooorsOIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKR/umloPIoA8cvV2ancqOglcfqau2Y+YVU1TjWLwek7/wAzVyw5I+lfNP4mfTv4UzViHAp11dwWcPmXMgRew7n2AqC5uEtLV55PuoM49T2FccZZry7a5u2yzfdXso9BVwVwpYf2ur2Ohk117kMltaDyyMZl5yPoK5618Piynley329pJ8xsY2It1bOdyIeEP+7gH0zzW3p5RQNxFaE97BHERla7IQSW5ryRhJckdTnURBJ5ZBR/TOM/SryTG0T98paM9GA/nWPrGpwPLsjG5/ReTWtpd0JbRPtG6OXHO5eDUxavZHRNSUU2jLutSWW6AtI2aRTkFOMH610Nh4hdbb/T7eTzV7x4IYf41nG1WOZ5YtoDHdwMjNT/AG1Io/8ASEAXpu6ily33ZNSMKqStf8zb07W7O/fy4ZCsv9xxgn6etaOa8sv5zc32LEbSpzvHauptL/WntkAMDMowWZeW+tZ2bdkc1bA2s4P7zq80hNcxB4int5vL1WAKvTzI+34VuSX9okSyvcwhGGVO4cik9Dknh503Zossahcc1BBqlhcPsiu4Wf03Y/nVieWOCMyTOqIOrMcCpZHLKLs0Io5qVayD4g08PtEjkf3hGcVbj1SxeFpEuoyq9eeR+HWixcqVRbxZeFOBrDk1mR8m1tSy/wB5zj9Kz7jxRNbyiKS0Qu3AIc4FVytalrCVZbI64sAMkgAdzVaS/tEOGuoQfdxXKpPJeHzLuUvntngfQVHqQtvJIXAbHar5NLmscEr2kzWvtXM0/wBn0912j70o5/Af41QuLRdpaSZ2c9SzZrH0VniBGxhtOORgVrMMfPIQc936fgKuCVjrVJUtImdp00kV5LGMs55Un0+ta52RASztgt/F1LfQVALi3hO+TzJQOyJgVUgulvp/PJ+Vug/uj0pr3dC2nN32RfzcSkm2jVfRn5/Sue1g30d4Jrt1kQLtwq4Kj1rurSeBIQDjpWB4hmhYHBGaqcfdvczoz9+1jEhvmRQyMGQ9xTzqvB5OaxlUtcHyWKknt0P4VmSa9cNez29ppy3JhcoXDEAkVzqT6HbKEVubk08tzJhAeaZY6nFZ6olumJO0rg/d9qq2tnrWrKFmKWcB6pEMMR7mpZtNi0xQkYwe9JrTUfuy9w7FsFcjkVVfrUejzefpsZJyU+U/hUj9TXNLQ81R5ZOLO0+G3El99E/rXc1w3w3/ANbfD2T+tdzXuYH+Av66nz+P/jy+X5BRRRXWcYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeQa7xr9+B/wA9m/nVnTzzVXWPm12/P/Td/wCdW7AYNfNz+N+p9N/y7XoVfF0xSyt0HR5OfwFc9cytCqnPJ6V0HjKMHRhMf+WMit+B4rkbuaK8tNm/a68qw7Grg9D0MIr00WY9UYcEkVU1HUpGXajHJ4rH+3HcYr5fKccCUD5G/wAKkkPzKwIZeoKnIocmdsYRubWiwDcGfkk8n1ruLSGDyQCR0rzyxvtgHbFbcWsEAYNbUpxictenKb0Nq8UW7F4n2H9DVCPUrWdzHKVilPBGMo/+FZOpamZl2q3zHgVNo1ojEE8sfvN60+e7shKlaN5bmla6ZCCWtXU5OcK4/rVpTcW/AY5/usMVpJpkH2bPAOKx7+d7RT8++MfwvyK0ceVGMZuo7LUytXlku7pYfmT+8T2rQ02ytI4wJXH0qe1uLe4jWT7NIGI6HBqfzUH3oZFX1GDUqKvcuVR25UrGfrcNlDamSEBm9qr6a0klvEt9M0kcfKox4XPar80mnzkI9wgOfuuuDU8SQKv7qUEf7Ef9aOW7uPntGzHy3FmINqR84/u1zsKZ1WV9pxgYGPet+aYRLkiYge1VotQtJZfLRZGl646U5a7ig3FOyLCXM/lhVjCr/tHFZ81hNc3aStIg2noMmtmKO4KbkhiUe4yazL/Urq0lRAIvmYL9yiSVveFCTb9wtR2SxqDIxK+rHA/Kldo04jXI/wBhMfzqWxH2h1eYl29TWtPBD5OQAKpRutDKU7OzOdOpW8bBPLYzt93cKvadbLO2+ZtzHuawNbAhvYZB2bBq5p+oFGwTURlrZm0qfu3ibt5aRqpA6EVxs4bT7pwP9UxyPY1u3mqDyzzXOXFwbmbHUHtSqST2Kw8JJe8WjqZVcZNZtzdPcNgZrr7HwvBc2MUryOkjDOMZ47Vy3jLS9U0q8hh05oVtpVyJguZM9xg9PrWTbeg6dek5csdzM1C+XS4gifPfyD93GP4f9o1peFNOWysI3cbp5SS7H1rJ03Q7hGaUpvlblpZWyxrroUVLe3VMkAYJPr3q4ouo77kQvDauwYcg4rJ1S5+0Slq2720W9dBGSkn8RHf0rL1HR2t+d7H60pJ/IqnKF7vc0fDsZSwdj0d8j8quSCm6TIr6bGE4KDa31p0lcszgqNuo2zsfhv8A6++/3U/rXdVwXw4P+l3g/wBhf5mu9r2sD/AR89mH8d/L8gooorsOIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADRQelFAHj+q/wDIZvT/ANN3/wDQjVyxrP1A51O6PrM//oRq/YdBXzUn7zPp2vdRieNLpmnt7JT8m3ew9SeBWNFoSOAy7lz1weKu+MCU1yMno0SkfqKuWN0ghCtjpW1NJ7no024Uo8pSsbGCFZbeRBJvGTuGc4rD1zw1HbGO40h2hmbJ2Zyp9sVvPcKNQiI6FsH8aNXbymt8+rD+VaaWLV3JM4htQ8hxFqULW0v94DKmtC3KyruhkWRfVTmtbWDaXtlsmRS+MZ71B8LNDCeJbyZ41e2jtypDDILMwx/I1k4roXOs6cHOS2K5RkZWcHHJrZ0a7WMAE13t7o1ldWrw+RHGWHDqvKmvPtU0S70u4OVJTPyuB8poWmqMaOKp4hOOzOhl1IFMBq5vVLzzp0UnKZyarebP0IqpdFlYEjFVKo2b06KizvvD7QtEvmEc1e1OWCOB9hGcVxFlfMIhg4qW5v2ePBJrZVUo2OaWGbnchhlWTVHducfKK7nS2hEQLAV5rFLsnLf7VdBb6gRGMNUU58rNMRRckkjpNXniETEY6Vyuhyr9vmkOMM2B+FMv78yIVLVn2Mpi3EdmzROpd3HSocsGj0uK8X7OAAK4vxPODdRsp+6wNIup4jxvIrLvpvObjkninUq8ysTQw3JK5t6ZqXlthjxWhPq6lMA1i6Zol9eWnmRREqOA2cbqnTwzqjthoiB7sP8AGpVRpWCao82sloUdRuPtLYU85pY4J3jEixv6HAOM10mm+ETG4e7kAH91eT+ddXDGkMSxxKFReABUX6mFbHQhaNPU8xFjd3LbUikP0U10Oh+GWidZb0YA52dz9a680wnFK5zVMfOa5Yqwq+3SuJ8Vkv4gw/3URQo9utdop5rnPGenSSwpf267nhGJFHdfX8KEzLByUauvUZCsf2MEAdKzWK7mC9AwNZMerOse3a/4A1csmeW0adhhWYBc+1b819j1PZuO5qWzrDqUiHoMflgU3XbmJ1wuM1U1p3iMFzGCfMXbgf3h/wDWrBuZLmQ7ihx9aJTtoFOlzWkbXhw5+0r24NXphiqXhYjyJ9xAlJGV9BV+44rjnuc9b+KzqPhuf+JheD/pmv8AM16BXnXw3fGr3Kf3oM/kw/xr0WvZwH8FfM+dzH+O/kHeiiiuw4QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApGO1SewGaXvVXVJRBp1zIf4Y2P6Um7K40rux5DIxe4kc9WYn8zWpZDCisiPqK27QcCvmT6iemhz/j63R7e0mXH2hSVC9yv/6/51yaXFwq42P+Vb3iuVpdfWInCoigfz/rWnp1kroBgdK3pw5tj0KUvZUo82py+ledc6jAjAqC4yzDAFdVe2CX0MsLnawOUb+6aS9tkiTC4zVq0bzGBz96In8QDW8IW0ZNSpze8tDh3067yQVXAOM5612/gF7eOzmtlXF0rb5D/fHY/h0rOsmVoct6VV0Kb7N4stsH5ZMxn8R/jWMopK6KxF61OUX01PRxQyhlKsAynqCMihaWkj58ovpGnu2Ws4c+wxVXU/D1je2MkCQxwueVkVeVP+FbFPUUzRVqkWmpM8hv9H1DTJjHNC5UdHUEqR7GoYbS6uGCxwyux4wqk17Qq08JxTUDv/taSWsdTzaDwVdyWTSyssdx/DCe49z2NYs+lX9tIUeGZSP9k17IUpNuKfIZQzWom+ZXPJdP8PajeyAJBIFPV3GFH4mu1t/B9mliIpQzTHlpVODn2HpW9eXLQJwpZjwAKzhe3bAuAmB2zzRZImrja1bVaI52fwPJ5n7u6XZ/tKQavad4OtYHD3UhnI/hAwPx710VndmcFXUq46g1axQop7Gc8dXtyuRXWNY0CIoVFGAAMACkIqyVqJlocTlUrkVBpSKQ1DKGk1G5pzGoJWqblpDkbmue8Z3ro9raIxCuC74784A/nW3G3Nc944hYGzuVHAzGT+o/rTTOrCpe2Vyzp+nW0lorFV3YrNuIhDLJGv3WBOPcVDaat5cAUnnFMF4s9xGOpJrpcotKx6ChNNt7FmUCR7JXxt2n+daWoWVulkCqrnFY8+77Ejr1iJJ+lVJtYJh27iR9KOZLcOSUrcvQrxMbXVYnQ4BcKfoa37oVzmnhr/UolXkKdzewFdPdL1rkqEYnSUb7ml4Bk8vxJGCf9ZG6/wBf6V6jXkXhh/K8R2Lf9NMfmCK9dr08ud6bXmfPZmrVU/IKKKK9A80KKKKACiiigAooooAKKKKACiiigAooooAKKK8j/aA0zW/FlvoPg7Q7GeW21K5M+oXJ3xQRwxDcEeYIwUu2McE5Ucc0AeuUV842mufEXSPAeg6dFa6vBf6M09heW1tpszS34iwsLwztazxBCCOWC7sH5vTrtP1vxlL4kv49XOv2ASK3bSbOLTUmt7tjECy3VwsLBD5nythogOccc0AewUV846d4m+LTaDrlxcm9GorprvHZnSJTLFdCUYMR+yLEy7TjZ5kpONwJ5xpalr3xPsJNbtoBq11arJpbx3p0pHmgilTN15SpGFlKNgbdrEd+maAPcbDUrHUTcjT722ujbTNbziCVX8qVfvRtg/KwyMg8jNUPGM3k+Hro55Zdo/E4rwbwXpniKy12GRNJ1GeC48bXt091f6QPNNu0CbZ/miHlbiPvKE5yOOlZ2peIfih/wjHh+XUxqdzeahp15JdWt5pscKwXEcjCH7salSygHax57dayr/w5ehtQ/ixv3O6h5cVt2owK8h+Gmuatf+K7rT9Svry4jh0+CZ47u0W3eOdvvjARTj0znjuetewW9eBODpuzPfVRVFdHIeNbc2+rxXXOyVAM+44/wqKy1hYlGXAIrV8eTo8FtY7AzufNLd1HTj681m6b4ahnhDtHk+5NaU1K/unp0ZRdGLqBdaqkw4YVtaTkx2bEHDKc/Qk1nS+HrSAbinzVsrIpjjIAUBAAB2xXRBNO8iaji42gcnPd/YZpbeQ4KMR+tSeGEOoeJLVkBKxHzGI7Af8A18Vqx6NDq00lzcIpZjn8KoXcUnh66W4sPkI6jsw9DWUoStfoa86lFwj8TR6StLVXS7xL+whuouFkXOPQ9xVqoR8/JOLaYoFTIKjXrU6CrijJscoqQCmrTq1RmxcU0inZoqhEUkYcYIqkNPw5KtgH9K0sUYqeVMpTa2KtvarDk9WPUmrG2nYpcU7CcmyMjio3FTGo2pSQ0yuwqNqncVC1Ys0RC9VZjVqSqc55rJm8dRsZ+apLyGG6sZYrr/Ulcsf7uOc/hUEZ5pdRRpdKu40+80TAY+lJPU0tquhwtjpq3TEl3Zc/KOmRV/8AsxbGRJUQqQefcd6k8PTqmCcVsapcpLEw46V1wiuW56tSpPn5ehlSN5cDqO52Z+tSxaMjw7gMjFRzp/oTSYzt2P8AhWjZakgg25HSqSTepnJySvE5uMHTdVjZRhCdrfQ1S+LOqX2j+GorjS7lra4e8hhMiorEKzYOAwI6e1XdZmEt1hOcntW3qum2mpWIttTtLe7h4JjnjEikjvgjFc8uWMk3sZ4yLlFPZs8vHjy88IeIdVhvXl1uLT5LZoJdio4kkP8Aq5DGuO2chM+xr1i5+LGs2+gjULjwLqsDpeS287zR3KW8MKJu+0Fvs5l8sjPPkjBBzjvgpo2l2tk9lDpljHYOcvbLboIn9crjB6V6kvgLwbLZRQnwn4eNsrGVIjpsOxWYAFgNuASFUE99o9K78BOMlJJdjwswhKPK5O+5zvh34lXPibX20zw/pen3S21lbXt5dPqLpHtmG4CAeQXlwO5VOeDg1g6R8b59U0y/1W38H6l/ZENjd3kN3++CEwBj5crmERoW2HBR5MHg88V6fe+FvD99cWk99oWlXM9mqrbSTWcbtAF5UISMqB2x0rnNStfBdh460/SJ/C+nNrGuwXT/AGpdPhIdFUeasrn5juDYxgg85r0DzTkLj46NY2F3NqXhwJMNLstTtY4L/wAxZVuWVVR2aNfLILDJww4PtnG0bxrr2n+LNYi1a4vPMuPGNjpYtre+EsMCSxMSitLCcx5GSFWNj2Ze/tr+GNAeN0fQ9LZJLZbN1NpGQ0C/diIxygwML0HpUdp4R8N2Uccdn4f0e3jjnS5RYrKNAsyDCSABeHUEgN1HagDzOy+OBaSwm1Dw75Om3kmoxLLBemaVWs0LtmMxqMMBxhjz29dn4f8AxPuvFPibTtJu9ChsE1DRf7ct5o78znyjKI1R18tcMeScEgdOe3bL4Y0ONYfs+j6bA8DySQPHaRgwvIMO6fLwzdz375rnvBXwy0Twl4gudas5J59Rnt/su94beFUj3biFjgijTJYAliCTjrQB3NFFFABRRRQAUUUUAFFFFABRRRQAVz0njPRE8QzaIlxcT6jAUWdLeznmS3LjK+bIiFI8jn52HHNdDXIJ4Es4PEep6tYalqVmuquj6hZReS1vdFV2/MHjZlyvB2MufrzQBi698WdB/wCEY1q78NX8V1qVrp1xfWiXFtNHDciLIJjZgolUMMHYx+tXrX4neHYLLT11vUUt7+W1tZroR28rQ2zzoCgkkClItxPG9hkVlxfBXw8tl9kmv9YuLaKwuNOsklljP2GGbO8RERgk4JAMhfA4qa/+Dnh69WeF7vVEsbyO0jv7OOWMRXv2YARGTKbgcKM7GXOOaANi0+JPhW61xdLh1N/tj3smmrutJljNzH9+ISFAm4emecjGaz/iZ5dzcW9pMiyRGJt6OAVYNxgjuMZotfhVocN7HcpdakXi1+XxEAZEx9okABU/J/q+OB196g8dvv8AEBX+5Eo/mf61xY+VqPzO7L43reiOY0HSNO0oOml2FpZI5y628Kxhj6naBmujg6is+1XitG36ivFu29T2JWS0OU8ZZTW4mb7vlLj8zWhpmqRpCBkYAo8dWqS20EqOBdKdoU/xL/8AWrmLfTbx0B8zAPoK6acnHY9Cio1aMeY6a/v0kUnIxS2xLW8X+0D/AFrnv7MnUhpZWKg8iusgjRmiSLhAoC+wraLcnqFRRgkkZ2l6isMZUkZHBFZ2v30c6EbgTVa/003d9PNZyPGrMSF7VmXGk3o++4Pvis5SlaxvCnC/NfU7/wCHxY6CQ3QTMF+mBXTVzvgq+t5dNSyiTyprZcOuc7v9r866Ks0eHir+2ldW1Hp1qdOlQJVha0ickh4p1NpRWqM2LRS0U7CEp1JSgUAKKDS4pKZIxqjNStUbVDLRE1QtUzVA9ZSNYkMnSqNx1q5IapTnmsWdECGM/NV2E8iqCn56uQk4461PU0ktDzy5uGtdSuVgjdoVkYLt54zTmvp5RgRSDPUkYqxpYDyuj9dxzn1zXR3FjELXIx0rqhBtHrzqRg0miK2VGRYfvRtDtJ9RiuUS2vhkRAMmeDntXS6flWVP7pZPwxxWho0EbWilsZxWnJz2MVU9ld7nE2we21CCS9AEauCwFdrNgrkHIPOawfEsaea2AOK0NMlMmlW7N124/LiuWrHlJxPvxjMhuRkkV6Hqlhc+JPhzcafY3r2F3faeYY7lOsbFMZ45/LmvO7g/NXp3gebzvDNp6puQ/gTXRl0v3jXkeRmUf3UX5nmM/wALdTl8NaNYQ6H4Usn0+7tri7tYJ3NvrKxqwIuD5AYHJ3DcJRknNVdJ+D/iK0GkD+2rW2+zW2qxA27ufsJulAiS3yoyiEE5Ow88CvdaK9k8Q+c734IeI7rw5q1jbS6FpjXOl2dh9mtZpTBdTQzpI93MfKBEjKhH3WPzct3r1L4d+DJ/CXiHxfOn2OLSdVvI7mytbUkCEBMPlNoVSTz8ua7qigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEUYFeWeJZfP8Q3rZzh9o/AYr1NiFBJ6DmvH7mTzr+4l/vyMf1rzcyl7sYnp5ZH3pS8ixAMAVft+oqjH0FXYOK8qJ6U9jl9TuDda7MHOUjOwD6V01sLf7EuNucVxniJW0/XJWP3Jv3in69f1p0OthYwua7KVRR3PQdF1KceTY1dWZUU445qewkAs1bPPlNj8jXM3d/8AaPlB610VlGyRxQscEIFPsSP/AK9VGV5XRU4csLMi0h4xFlscU7UJojExXFc3cXj2FxJBKrBgcYxVSXVMggh8fSo9pZWNVRbfMbPhy4MPiS1ZCcO3lsB3B4r0uvO/AdnJe6iL0qRb25+8e7Y4A/nXolZnmZi06qS6IevWp0qutTRmrieZImAp1ItLWxmxe1FFLTEAp1IOlJmmSPpDTd1G6i4xDUbU9ulRsahlIY9V5KnZqrynispGsStKapymrMpqnIawZ0wIh96rcJqoOtWoanqaPY4/xFA+m6sZYlIhm+dfr3FSR6zuh2HOcVJ4rmNxqsdr/wAs4kHHuef8KZDoavGHAbH1rphzW0PTg4unF1NyzojtJmUj5fNGKbJf/YLqaAtjaxx9KsaWnkZtscK42/iKrS2Qv7qaQrklzW2tlbcj3XN82xj39015MI4QXdzgAd66a3tjbWUUJ6ouD9e9c9qFmbJ90Y2spyCOMV0WnXX22wSVvv8A3W+orlq36hiPgXLsUbwY5rvPhjKX0KZD/wAs7hh+YBrib1eOK6n4WyfJqUPo6uPxBH9K0wDtWR5eOV8O/Kx3lFB5FIBivdPnxaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAgv3EVjcOeixsf0ryG3GTk969S8TS+ToN6//AEzI/PivMLccCvIzJ+/FHsZarQky3H2q5F2qolW4u1efE7ZnPeLlhvri3tGXLxjcWBwRnt9KqW/huHZuMeR7mm3EhPiC6Zj/ABkflxXU291CtqASM4rspQjLc7uaVGnGMTm10y2s7mKUQglWB55FaqsEaWR+doLGoNUmUxn3NKQZLa7X+IxHH161orLRFNuSvIq2ES6hM0swBZjTNd0mKFNwUCoNJuxAgJYAiq+s6t9oXaXzUXjy67mqjPn02LvgK9aDVpbFv9XMpI9mH/1s16BXmXgmF5/EkUi8rErOx9OMfzNem1iebmKSradhakjaoqUGmmee0XEbin5qqj1Xm1azihv3WeOV7GMyTxROGdBgkAjOQSAcZraLuZNWNKnCvNvC3jLV7rwknjHXn0m28PSQS3LW8MUhngjGdv7zcVkY4wVCL168YMNh8bPC93ZXk6JfCWDydluoilknMpwip5cjLuzwQzKR3xWyhIzckeo9qaa4rUfiJZ6Vd/ZNX0fVrK7Gn3GpGKQQOfKhGW5SVhuOOBn64rIuvjHocFt9oGm6xJCunQarKyRxfuoJWCqSDICSCRkDPtmjkbFzI9KpAa5zwp4wsvEuoavY21teWt3pbRCeO5VBlZU3xspVmBBXnnBHcCuiNQ1YtO4pPFROaV2xUDNms5SLSEY1BIeKlNQSnrWMmaxRWlNVJKsSmqz9ayZ0xGr1qzDUAFWIaXUp7HK+KImttZW4I+SVQQfccEfyq/Z6wgtApAziqWt6gdVnNnbIGgjb72OWYdx7VSuNLe3QEswOM8Guqm5RV0elCClTjGpozY02Yz3Zf/bx+lLpFyIyxbGdxz+dGjoscNuFGMLuJPc9zWJdCf7TcS2nMDOSvNatuKTEoKbcS/r1wsu5uKf4XydNlJ6eZx+Vc2zzXEwhwxkY4C+tdtY2v2LT44ONwGWI9T1rlrT5grpU6ah3Kl4eDXQfDJ8apfpn70Sn8ia528PWtj4dNjxBKv8AegP6MKWEdq0TzsUr0JI9Pooor6I+bCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKO4oA53x5L5fh91H/LSRV/XP8ASuBt+ldj8R3IsLNM8NKSfwB/xrj4B8orwswletY97L42oX7ssp2q1F2qotWojXLE3mjkPE6mw1cyEfu5xvU+/cVn/wBt7RsXLH2rsPFNvBcaJMZ+GTDRt3DdK5vQtNiJGUGfWt4XeiPSw9WMqV5dNCO1uJrqaPzkZItwyTXTRr/pDhcdQR7g0t1ZRQ2x2gdKr6TJl4Ax77fyNdMY8rsyZTU480TAutKeS9mW2lIhDEdOaoXui+WuS75+tdjpMYBkVhyGIP51Hq8C84xUOmrXLVdqXKQ/D+8sbRXsmBS7lbPmMfv+g9q7ivEdfuoNKdbmeeO3jU/fdgoBrt9H8Uazr+lwNoGlE5G19Q1EmGHI7rGP3j/koP8AerNRbPPzCmoy9onuds7KiM7sFVRkknAArmJPGEF47w+GbOfXJ1O0yW5C2yH/AGp2+X6hNzD0pE8IR3ziXxRfTa3JwfIlHl2in2gHB/4GXPvXTxRpFGscSKiKMKqjAA9AKPdXmedq/I5f+wdX1jJ8S6s0ds3XT9KZoYyPR5v9Y/4bB6iuj0bTLDSLQWul2dvaW4OfLhjCgk9ScdSfU1ZA4pVHNPmYuVHP2ngLwza+esOm/uJlkU2zzyvbqJBh9kJYohIJGVUcEjvSjwH4ebSpdMmtry4091RBb3OoXEyRhfu+WHkPlkdimCK6VTS5rXnl3I5F2OYv/h/4c1BYft1te3MkUUsKyy6lctKY5Bh0ZzJuZSP4SSPQVG/w68KvazWzaVmGWxj011+0S828ZDImd2eCBz19TXRT6jZ25xNdQoR2Lc02HVtPmbbHeQFvTdj+dPnl3H7F2vy/gV9J8PaXpGpajqGnWvk3eoCIXMnmO3mCJNkfBJAwvHGM981pk0uQRkcg9xTG6VMncSVhjmoyaVzzTCaxbNUgJqvIeKlc1XkNRJmkEV5KhYVOwqJqzN0NFTLxGxHXBqFetY+pX0lxM1tbMViU4Zh/Ef8ACqhFyZpCm6jsjD0W5S2fEhG73Namp3qyx5BHI4qOfSUMfzqCOtR6fpily0jlokb5VPUmupKS909OTg3zlz5otMf+8ypEPx6/pVtbRVsB0qtqj/Zra33/AMU2T+VJdagotQFPFXdLcws5K66sw4rn+z9bikXBXdg/Q9a7Sc8GvPubvVIkXks4H613sx44riqbhjEk4vqZt30Na3w8I/4STB7wN/MVj3Z4Oa1/h5/yMq/9cX/pTw38aPqcOI/gy9D1Kiiivoz5oKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApP4qWjHNAHD/ABIf57BPdz/KuZh+6K6H4l5W6sG7FXH48VzNvIMV89jf48v66H0WCX+zx/rqWx1qeI1VDVLG9c6ZtJGV42lZdPtkXgNLk/gKqaROBGpBrT8R232zS2CjLxneP61xdtetbOUaumlKx2YePPSsuh2V3c7ouWrMsbkLK655Vt1Zkmol04NZ8lyySeap57j1rWVTU3hRsrHU/bfJvpOcJJ8w/rTL2+UqctXPNcG4hUq3zDke3tVGe7YjDZBFJ1BqjdlbV7Sxm1MXrQJJdcASPlio/wBnP3fwxXqngViPD6A9PMbH6V5REj3NyiKCSTXsei2psdKt4H++q5b6nms3Jvc58eoxpqK6s1Q9ODVVDU4PSueNylpWp4NVBJUiyU0yXEluLmK1gaadwsa9TXHajq11qkpSEtFb9kU9frSeJ9RN3efZoj+6hPOO7d/8KbpaKqitoK56WHoKlD2klqNj0guuWzmo5tJCjgV0EcgUU2bDDOa25EWq87nP2z3mnPm3ndP9nPB/Cuj03xHDKVivysMx4Dfwt/hWdcJx0B9Ko/Y43kJONxrNwKnCFZe+te52gnhkOI5Y3PorA0E1x91pEcUQkRsN6jim2eu3Vo4t5FNyuOCzYK/jWcoNHK8HdXpu51rnNRMM1iNrtwvzPaKY/ZjmpZNftfs4eLLzNwIjwR9faspQkJYapHoabDiqd3PHbRGSVsL0HqT6Csz+1705d4IynoM/zqhPff2hfqHUoiD5UJ/M0eyd7M3hhpX97Ysvqty6sYbcKpHBJJIrItrlraXbKMA9DXSiS3jtyCBmsw2KXr7nUrBnk929hXR7NR+E6qbhFPSyFEz3JCRHjufSrgKwBFRdzAfKv9TUvlQWFo8hTy4E5xnlj2Gaz4LkEmRyC7HJq9tyU+fbYg19JLi3Xz3PHK7eAK5xY7uRvKjDy+m0Zra1u/EkZVRwKf4IkZru5/u+Xz+dYVGr3OhSdKk5W2Lfh3RmsQbm7A+0EYVf7g/xrWk6VPKcmqszYU5rlbuebOpKpLmkZt2ctW78N1J8RO3ZYW/mKwJjkk11XwwjzqF9Ie0SqPxP/wBatcIr1omWLfLQkei0UUV9EfNBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHH/EuNDplrKxw6S4Hvkf/AFq89jmC967L4o3Id7GzU/MN0rfyH9a4dYjXz+OknWdj6LL42oK5pxTBh1qdG9KyFVkPGatRSsOtclzraNWN65nxDoG4tcWgyvUoOo+ntW7FKCKtI/pVxlYUJypS5onlUoljyCDxUPmt3NepXml2l5kyR7XP8ScGs3/hErJmyZpMf7orVSTO6ONpte9oefLKytlCc+1XLS3kvGbKNtUZY44A+teh2nhjS4MExNKR/fbj9K3IIoYYvKiiRI8Y2qoANVcxqZhFfCrnIeENNsrTUts65uSu6HPTjr+Ndo1cbrEH2FnlhJBtJldD/snnH9K6/cGAYdCM0p6HLiveanfcKdmo808c1KZytC5qG+ufstlPP/zzQsPr2qbFY3i6Ty9HZR1kdV/r/SqRVKHPNROStpWZmLHLE5JPc1qWt35Zway44i2CvBp0m5OgzW0W0e3KKlodIL9cdaesjuu5DXHLelpTGcrIvO09x7Vp2WosBtzWiqdzGVCy0OgilWYFQyq/dW6Gq9xCwbKEo3oeRWXG5uJ/lrWjtr2KPdG29P7rciqT5iHHke5Az3TLtI3D2OaqrhJMuNre9XGuo92JYmjb1XkUvnW7jmWQfVc0tyk2ug+S8hNtsx81YgjZL3zhG5ixjcBwD6VtIkJIC3EWfcY/mKnZPKTdLOFTpnP+FNq4ozUNist4rQ7Ahz9KzprG4knSaFdnPJY44rTku7fOE86ZvbgVGb94gSLRQPUtSdnuxxcl8KFgtNq77uTdjt0H/wBerJvG6W0WSOAzjp9BWLaXcl1OHuGywOCOy/StxbyGKI5x0pxa6Ezi/tamDr81zOm25ncqOQvQA/SslbplXa5wRV3XbxZidvSq2maXNqoCwlQVHJY4GKwm9TrhywheWiM+eVpWCrliT2713PhvTjp1h+9AFxL8zj+6OwpdI0G30w+axE1x2YjhfoP61elkArCUjixOJVRckNhztVK4bNLLOB3qlJKT0rFs54xGzYxXZ/DAA/b2HX5B/OuKPIya6z4a3Cx6jdW5P+tjDL7kH/69dOCdq0bmOOV6ErHolFFFfQnzYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQSAMnoKKzvEV0bLRbycHDLGQv1PFKUlFNsqMXJqK6nl3iG9Oo6/dT9UDbE/3RxVdUHWobdctk9atAV8xKTnJyfU+pjFQioroIqAmpPIBFOReasItFiXIpmIr0p8cjIQDVzywR0qNoPak4gp9x8coIqZWqmYivSljkZTzQnYTSZoK1SK1VY33VKDWiZi4mJ4kQtZam3Y+Wv6VvKCkaL/dUD9KwdcJC3it9xljk/I81v53cjoea0nqkb1XaEf66ITeKejCo2TNMGVNZGWjLinIrn/G/wDyDrbH/Pb+hrZRzWR4uG/SUb+5KD+hFVF6mmHVqsWYFn2zV1rfdzis6xcFhXS2UasgLV1wVz0asuTU5bVtKaaMPHlJk+ZHA6Gsm11ALKYbwC3uRxg8K/uD/SvTGtUdcACuV8SaHBcRkPGppyp21Ip4jmdilZXDRncezV0sGsDyNpx0ryyT7doVzmEvPafxQuc8ex7GtzTdWtr9c2c43jrE/DD8KmMnHY2nTjU3Ojur1C+D1NamlxwzICxArj5d4kYtnIAqe21B4ujYoU7PUJ0W42iddqNtbxL8jA1y924E8TZO3OCKbPqrunLVSeRni3N68USmnsOjSlFe8zqLGeBFyR0qDVr5HUhQAK59L1kXGawLi/uIPEghnldrO/T9zuPEcqDlR7Mo3D3VvWjnurITpqMk2dGJzFKHHRhmia/LAgV0ugeG4rnTlmv1kVn+4oOOPU1fTwtpkTZKyvjszcfpWTlYzni6MZNPocNa2lzqE4jgQsx/ID1Nd5pViml2giQ7pDy7+p/wq2kUFnFsgjSJfRR1qpLKWOFrKUzlrYh1tFoh8swGaozSM3SrKWzyHLZxVlbVVHIrOzZhzRiYwhdzlqm+zhRzWkYwOgqN04NHLYftLmXIlWNBuTY6zaTg8LIAfoeD/OkmTniq+OeOtJScZJotpSi0+p7ZRVHRLj7XpVrMTksgz9e9Xq+oi1JJo+VlFxbTCiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuQ+I915emQ2wPMr5P0FdfXm3xBuPO1tIQeIkH5muTGz5aL8zswMOesvLU52FcCrCDJqNBgCpohzXgo9+TLESVYVKbCOlW0TNaJHPKRCEpSlWhHQyYp2I5ikyVE8QParzJUZSk4lqRSCsh4qVJM9alaPioZExyKm1ir3GXtnDfKom3fL3U447j6VbXAAA6DiqqOQcGp1bNUncUr2sydTTigYVGpqVTVGZGYcdKp67bmTRbsdSE3D8Oa1AacyLIjI4yrAqfoaEhwqOMk+x5daSfP1rqNNn/dgE1y2oWsmmanLbS/wH5T/eXsa0LK5O0YNdFOVj3K0FUjdbHYxTDbnNZmqzK8bc8iqsV03l4AJNUb4yyggAjNbOehxwo2ldnP6s8bMQxrO8NaPHf+L9O8uENslErnHG1eTmtaTSmkcly1bng+eHRtQMcka7LjCGUj5l9Pwz1rld73O2s/3TUdWdXq2kQ39uY9ixuOVdVAx/9auQuvCmoxsfLjSVfVGH8jXpBWgIKR41HG1KSstUeYxeGdUdgPsjD3YgD+ddHZeD0Nti9mPmnoI+i/n1rrAAKCcUXKqZhVnotDiZfAxL5jvVCe6HNRar4Cgn0iZIbjOpR4mtJWXCRzIdyEjuMjBHcEiu3dsVXlmAo5rakSxVapHllLQz/D+tR63odrqCoYmkUiWFvvQyKSrxn3Vgy/hUlxdY4WuWiJ0XxpLb/d0/XMzReiXaL86/8DQBvrG5711aWoJyaiad9NjOnZLUqCOSc5PSrtvZquMjmrUUOBxU+3A6UowCVToiuYwo4FQyCrUlVZKohEDDrUEg4qd6hk6VDNYsoy1UfhquTdaqy1kzpieieArjzdHMRPMTkfgef6101cF8OLnF3dW5PDIHH4HH9a72voMHLmoxPnsbDlrSCiiiuo5QooooAKKKKACiiigAooooAKKKKACiiigAoo70UAFeQ69N9p168kzkeYQD9OK9clbZG7H+EE14sW3zSP8A3mJ/WvMzOXuxieplcfelIlFTRVCKni7V5KPWlsXoByK0IV6VRt+1aUFbI5JkqpSMlSr0pcVdjK5VMdNMdWytMYcUrDUii6YqvIBV6UVUkFS0axZWKCnKMCkbik3VNjQlDVIrVBkGnK1Mloto1TpVJGwasxNTTM2jnvHmnrPYw3SACeNtmf7ynt+Fcxp1nKcZrrvGrkadb46GX+hrn7S8gtoWnu5o4YYxueSRgqqPUk8CtYK7PWws5LDm9p2nZUFhWjLpkezO3msHR/FJ1O5hj0XTri7sywEl/J+5gC9yhb5pD6bRtP8AeFdczDyzk13RgkjinWcndM5bULVYwcCuX1AkOe2K67WZlUEZrh9TuB5hxXLVsj0sJeW56rolw11o9nO5y7xjJ9T0P8qvVn+HoTb6HYxPwyxLke55/rWgTgVieFUtzu21xCcVFJIAKSSSqzvu61LYKIryF+lQlCTU6YqQAUrXKvYwvE2ivrGiSwWziG+jZbi0mP8AyznQ7kY+2RgjuCR3q94X1OPXNEtb9IzE0ikSwt96GVSVeM+6sGU/StReK5a1/wCKf8cSW5+XTtezNF6JeIvzr/wONQw943PetIq6sZSdnc60DFI1OpGpAV5KrSVZkFV3qWaIgfvUD9KsNUEg60maIpT1Tlq5P1qnJ3rJnTA1/As/leJIQTgOrL+mf6V6pXjOhTeRrdjJ2Eqg/QnH9a9mXoM16+WyvTa8zx8zjaon5BRRRXonmhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBT1mTydJvJP7sTH9K8ehHAr1jxW2zw5fn/AKZEfnXlEIrx8zfvxXkezli9yT8yYVPF2qEDmrEQrz4noTL1v1rSg6Cs23rSg6CtUckyyvSpAKbGOKlArVIwYwionqwRWL4v1b+wPDGqav5H2j7DbPceVv2b9ozjODjp1wafLfRBdLUsyVXda4Lwt8ULbWJbxtRtrK00+10+PUJb61vvtUMW848mRvLXbL/s89DWyvj3w09pcXH9oOggljgeKS1mSbzJBlFERQOSw5GFORSlSmtLFxqRfU25FqAjBrlv+FgWcnjSPQxYX6QvYG9+0y2k8bKRIV2mJowwXAzvOF7dakfx94Y+zwXH9p/uZ7R76Nvs8vMKEhmxt7EHjr7VDpT7Gsase50uaN2DXJv8Q/DCLI0moSosZj3l7OdQgk+4zZThWyMMeORzW7q+pWulWv2i+kKRlgihUZ2dj0VVUEsT6AVLhJbo0U4vZmtG4NM1HVLLSLQ3WpXcNrbg43yuFBPYDPU+wrk1vvEGscafbLotmR/x8XqiS4b/AHYQcL9XOfVa09G8O6dZXYvZxLf6kB/x+3r+bIP93sg9kCj2ppJfEyHd/CUdd1HVvEmnMugaVJb20Z3i+1JTHuAH/LOHh26/xbPbNcpp+hW32iO41WSTVLpDlXucFEP+xGPlX64z7mvXklHY1xvifT/sl2Li3XEEpyQOit3FaKfY7ME4t+znr2NPTbslMVpNdExkZrnNKfIHNaM0mxa6IydjepTXMZesSSMxqj4f0V9T1JXmUi1iYM7Hv/s/jU9/LlutdB4SR006R2yBI+V/DvXNUZrUm6NFuO50nm4pry5qoz89ajaTPFZ3PHUCWR8mmhuajBpy1JVrE6GpQahSvEPDmj6lpvjCI2umzanHdTTT3Nzf6VLb3VtuVuGuM7JhyBtywPoMVtThzJ6mFSXK1oe8oeaZeWFtfrCt3CsohmSePPBR1OVYY/zjI6GvAW17xloPg+xeZL3RLS30Oa4DW2koFN6JWCxyr5RWFduD0UHPXJrXTXPiJcQXd5bPqjJGdJNskemxtHOs0INy2fLywDckqRtJxx0rZUJd0YOsux7nikIryJtW8dwi4trr+1hYQa/LayalFpqyXX2IKDG6RiIq4LZBdYzWZa3/AMQJJtO1C40VptTj0m+8uabTkWRnDfud7bcxsw58sFQfSj2D7oXtV2PYTfWcl/LYpdW7XsSCSS3EgMiKejFc5APrSSCvLfhfb6vN4/1DVNWTV5TcaPbLJc6hYG1zMD88YHloPlOccHjueteqyisqkOR2N6cuZXKz1Xkqw9V5OlYm6KcwqnIKuzVTkrOR0QKyt5cyOOqsG/I17hE2+JGHRlBrw2X71e0aPJ5uk2b9d0Kn9K9LLHrJeh52aLSL9S5RRRXrHjhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBi+NDjwzfe6qP/HhXl8Ir0/xoM+Grz2Cn/wAeFeYw9K8TMv4i9D3Ms/hP1/yJlFTxiokqdK44nXMtwVpW/Ss2AdK0rcdK1ic8y9GOKmAqKKpxW8UcshpWszxHo8GvaFf6VeNKlvewvBI0RAYKwwSCQRnn0Na1NIqrdSTze6+FOgTJcRmS+W3utPi0+6hSRQlwsQHlyuNv+sXauGGOnTGQa9v8KtFtbEW8VxcpJHPDcwXMNvawSwyRbtrAxQqH++fvhv559LYVDItJzl3KUY9jhpfBUDa7a6xcarqc+oRWjWMsj+SBcws5fY4WMAYJ6oFPA5rmh8JdGjt0t21HVpIY7OWwiVpIv3cUjFiARHkkEnBOfxr1KcVTk61k6k1szdU4vdHn2pfDPR7221CGW51AJfW1rayFZEyFgIKFfk6naM5z7Yrs3qZ6ibpWcpOS1ZvCMY7IiJwaXccU1utJmoNLEsUxB5NSXiLd2UsLfxLx7HsazpJCGqWG46ZNOLE4tPmRg6a218Hsa0LyTMeax432Xk4H3RIR+tW7p2eLgV0xeh6so3kmVIIW1DU4rZGwGPzN6AdTXdoI4IkiiAVEG1R7Vx3hQEatKzdVjP6kV1DvzWE3qcmMbc1Hoh7v6UzdzUe7NKvWoOWxOhqZagjFWUFUiJEqCpkFRIKsKgYFWAIIwQe9UjGRxOoa94C1eGTVNWt7S+trEHF/daW8kIw4XbHM0ZVjuIAVCST0HBqfXfiFbxxaGfDrxTtca/baPeRXVvLFJAsgYn9221lbAGCRjrwaSL4Y6Z/YEmhHUtW/sXO+3s98WLV/MDh438vfkHONzMOTkGrkXwy0gzJc3F5qNxf/ANrQaxLdyPGJJ5oQQisFQKEAY8KoPvXZFQOOTmXY/iJ4VknliTVM+Ws7CQ28ojkEIJl8uTbtkKgHIQk1L4f8a+H/ABJfGz0e+ea5+zLeCOS3lhLQtgCRd6jcuSBkZrEj+EmgxpHB9q1J7G3W6WztGkj8uz+0AiQx/JuJ+Y43lgK1PD3gLS/D+r2WpWU9689ppCaNGsrqVMKvvDHCg789849qclC2goud9TopRVOWr0oqlMK5JI6olSSq0lWZKryDrUGyKsoqnIOTV2XpVKXvWcjoplGc4NeweFX3+HrA/wDTICvHLnrXr/g3/kWNP/65/wBa7st+N+hxZn/DXqbNFFFeyeIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFAooAy/FEfm+Hr9QMnyify5/pXlUFewamnmabdJ/eicfoa8etjwK8fMl78Wezlj9yS8y0vap0qBe1TJXBE7pl6DtWlbjpWZb9q04O1axOWZejqUVClTCuiJzSFpDS0EVRJGwqFxU7VC9Qy0UbgVQkrRnqjKKxkdMCq9RmpXFRtWZsiBxTKkeoj1qS0V5l5qs+VNUtX8R2VldGzhEt9qWMiztF8yQehbsg92IFZcmn6zrHOr3X9m2Z/5c7GQ+Yw9Hm4I+iAf7xqlDq9B8/Ramfr2pJa3s1rp8hvb+Y7jZQLvkXPckcIPdiBUWmaf4umQm/NvEMjbEjhiB/tPnr9B+JrpdN06z0qAQadbRW8OclY1xk9yT3Pueav2shYv9apzsrI3jWqqzbG6BYXFrNJcXTRhmQIEQ5x3yTWyTUMR+Wn5rNu5nOTnK7HipUFRLViMU0ZsljFWEFRoKnjFWjGTJIxVqMVFGKnSrSMZMniFWF6VBHUw6VtEwY6mt0p46U16tklaUcVTlFXpKqSisJG8ChIOTVdxVuUc1WcVkzZFKYcVRl71oTDgiqEo61nI6IGfcDJr1/wAIDHhnTh/0yFeQ3HBr2HwoMeG9O/64rXdlvxv0OPM/4cfU1aKKK9k8QKKKKACiiigAooooAKKKKACiiigAooooABRQKKAGyrvjdT0IIrxeIbWI9Divaj0NeMMMXEg9GP8AOvKzNfD8/wBD1sr+0vT9Sde1ToOlQJVmPtXmxPRmW7cdK0oKzoe1aEJ5Fao5Zl2M8CplqvHVhK3ic8iQUHpQOlB6VoQRtUElTtUL1DKRTmrxb4yeONb0bXrXT/CxlL2VudQ1AR2pnDRbgAjEK2wYDEtxjjkV7VNWPJplgLq6uRY2ouLpQlxL5S75lAwA5xlgBxg1MZKLu1c1aclZOx5prvxUFoNQn0/So72xs7K2v2lN35bPHMQBtXYRkZHBI707VPiWtnPqca6V5n2LULaxybnBcTKTvxtOMY6c59RXbf8ACNaEsEsCaLpiwyxrE8YtY9ropyFIxyAeQKjvPDui3V4bq60fTprr5f30lqjP8v3fmIzxgY9MVPNS/l/rQ0Uav8xzeh+Mp9S8Ty6Pe6Z/Zkg80wpcvIJpkQ43qvlCMqfaQ1cv9K1TVLuVb3UjaaYGwlvYEpLKv+3KeR9EwR/eNaljoOkaZcyXGm6VYWk8gIeWC3SNmHXkgZNXGrKUkneCNoRbVpsztO0yy0q1FtptrFbQ5yVjXGT3JPUn3PNSSjNWGqu/U1m227s2irbFZhzTLP8A1kg96mbFQ2X+ukoNOhpxHgVKKgjqYUiGSJ1q1FVVKtR1SM5FlKnSoI6sL2q0YssR1YSq0dWY60iYyJ0qUdKjSpB0rZGLHjpSNSg8U1qpkkL1Vlqy9VpawkbRKcvU1WerMvWq0lZM3iVJe9UpRV2aqUlQzogZt0Otey+HV2aDp6+kCf8AoIrxy7HBr2jSBt0myHpAg/8AHRXflvxSOHM/hiW6KKK9c8YKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvHb9PL1O6T0lYfrXsVeTeIY/K1+9X/poT+debmS9yL8z08sfvyXkQxnpViOq0Z6VYj6V5UD1JlyLtV6E9KoRdquwnpWqOaReiNWUqpEelWkraBzyJQcUE0UlamY01E9SmonqGUipNVKXvV+YVRlHNZSOiBVeom61M9QPWRuiJ6gc1NIaryGpNERsaglFSM1RSNmkaIqyNzTbHmeSllHNNsDi4f6UFdDTjqcdKgTrUwpEMlSrMdVkqzHVIzkWo6nQVBHVmOrRhIljHNWY6gQVOlaRMZE61IDUS1IK1Rkx2aRjSUhptiGPVaWrDVXkrKRrEqSjmqslW5BVWQVkzeJTmqo4zmrkwqo/FZs6IlC5XrXtFgNtjbr6RqP0rxqXlwPUgV7TAMQRj0UD9K9HLFrL5Hn5o9Ir1/QfRRRXrHkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5l40j8vxHMf76q36f/Wr02vPfiEm3V4H/AL0WPyJrhzBXo38zvy52rW7o59OlWYjVZOasRV40T2KhciPSrcRqlHVuHqK0RzyL0R6VciqlDV2PpW0DnmTUlLSVsZDTUT1I1RP3qGUiCWqM1XZapTd6ykbwKr1XkNTvVeSsWdESCQ1A/Q1M4qJulI1RWamP0p79aYelIsgkFQ2hxcv9KsSDiqsBxctQUtjWjqYVBD0qdaRDJUqxHVZasRmqRnItx1ai61Viq1H1q0YSLKCpkFQpU6VpExkSLUg6VGKeK1MhaDRQaAInqB6neoHrORoivLVSWrUvWqstZs2iU5qqPVqXrVZ+lZSOiBTxuuoV9XUfrXtKjCge1eN2kZfVLRfWZP8A0IV7KOleplq0kzzczesV6hRRRXpnlhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyHj60MwtJVGSNymuvqhrFuLi2UEZIOaxxEPaU3E2w9T2dRSPMFhZTyKmjBFdJcaZyeKpPYFTwK8V0JRPa9vGSKEY5q3D1pPszKelSRIQelTZoltMtw9KuR9KpxcVbQ8VrEwkTUUgNKa1uZjGqJ6laoWNQykQSdKpy1ckqpL3rKRtApvVdxViSoHrNnRErvUD9KsP0NV3qTVFd+pqM1I/U1E1Isic1Vi/4+DVl6rxD/SDTKRqQfdqdarwnC1ZSpIY9anjNQCpYzTRDLsRq3H2qlEauRGtEYSLcdTpVeOrKVpE55EgpwpAKUVojMcKRqcBTWFUIhc1C3Sp2QmmmMms2mzRMoy1Ukya05ISRUDWx9KjkbNYzSMl0JzTPILHpWuLUk9Kt21hkjIpqi5F+2UTL0bTi2qWrEfdkBr0isXTrMRzo2OhzW1XrYWl7ONjysVV9pJMKKKK6TlCiiigAooooAKKKKACiiigAooooAKKKKACiiigApHG5SKWigCnNbhu1UZbQelbGKayA9qylTTNY1Gjn5LP2qA2eO1dG0IPamG3HpWEsPc2jXsYAtiO1SLAR2rZNuPSmmAelZ/VrFe3uZYiIpChrU8j2pDbj0o9gw9qY7qfSoWU1tNbZ7VG1p7Vm6DLVVGE6mq0ymuhaz9qry2Oe1ZOhI1jWRzcimqzg+ldI+nZ7VA+mZ7Vk6EjeNeJzcg61BIDjpXStpRJ6UxtIyOlL2EjVYiJyjg88VEyn0rrDov+zQdDz/DR9XkV9ZgcY6n0qKGNvtB47V239g/7NOi0FRKTtprDSD63BHMRxtgcVbjib0rqE0hQPuVMulqP4af1WRm8XE5YRN6VLHC3pXTDTFH8NSJpyjtTWFZDxSOfihb0q7FCfStdbADtUyWeO1WsOzKWITM2KE4q1HFxV5bX2qVbf2rSNAxlWKIipwiq+LenC3rRUWZuqURHSGOtH7P7UfZ/aq9iyfaozfKpRDx0rTFsPSniAelNUGDrGR9nzQLTPatkQj0pREK0VAn2xkx2fPSrsNsFxxVsIBTwMVpGkkRKq2MjQKRUtIOtLWqVjJhRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAYoxRRQAYoxRRQAmKNtLRQA3YKNlOopWC4zYKPLp9FFkO5H5QpDCD2qWijlQXZAbdfSmm2X0qzRS5UPmZW+yr6Cj7InoKs0UciDnZW+yJ6Uv2VPSrFFHKg5mV/sqelJ9kTOcVZoo5UHMyv9lWj7MKsUUcqDmZB9nFHkL6VPRRyoXMyDyB6U4RD0qWijlQczI/KFHl1JRTsguxmyl206iiwriYoxS0UwExS4oooAMUYoooAMUYoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the different parts of the colon (also known as the large intestine), the rectum, and the anus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13250=[""].join("\n");
var outline_f12_60_13250=null;
var title_f12_60_13251="Extension injury to olecranon with valgus stress";
var content_f12_60_13251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Extension injury to olecranon with valgus stress",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) A fall on an outstretched hand with the elbow extended places a valgus stress on the forearm.",
"    <br>",
"     (B) This stress can cause a greenstick fracture of the olecranon with or without a radial neck fracture or medial epicondylar apophysis avulsion.",
"     <br>",
"      (C) Radiograph of a valgus extension fracture of the olecranon with an associated radial neck fracture.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Erickson M, Frick S. Fractures of the proximal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"      </div>",
"      <div class=\"contractual\">",
"       <br/>",
"       <a href=\"file://www.lww.com\">",
"        file://www.lww.com",
"       </a>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13251=[""].join("\n");
var outline_f12_60_13251=null;
var title_f12_60_13252="Post-PVC HCM hemodynamics";
var content_f12_60_13252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Post-PVC HCM hemodynamics",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    LV and aortic tracings showing LVOT gradient with PVC and post-PVC HCM hemodynamic changes. Post-PVC beats show rapid aortic upstroke, narrow pulse pressure, and spike and dome configuration of aortic pressure wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13252=[""].join("\n");
var outline_f12_60_13252=null;
var title_f12_60_13253="Telmisartan: Patient drug information";
var content_f12_60_13253=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Telmisartan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     see \"Telmisartan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Micardis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Micardis&reg;;",
"     </li>",
"     <li>",
"      Mylan-Telmisartan;",
"     </li>",
"     <li>",
"      PMS-Telmisartan;",
"     </li>",
"     <li>",
"      Sandoz-Telmisartan;",
"     </li>",
"     <li>",
"      Teva-Telmisartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691456",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop heart attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop strokes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to telmisartan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11071 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5A1610FE52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13253=[""].join("\n");
var outline_f12_60_13253=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224973\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224974\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023011\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023013\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023012\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023017\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023018\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023020\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023015\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023016\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023021\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023022\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=related_link\">",
"      Telmisartan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_60_13254="Cyclobenzaprine: Drug information";
var content_f12_60_13254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclobenzaprine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/23/33140?source=see_link\">",
"    see \"Cyclobenzaprine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26709?source=see_link\">",
"    see \"Cyclobenzaprine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amrix&reg;;",
"     </li>",
"     <li>",
"      Fexmid&reg; [DSC];",
"     </li>",
"     <li>",
"      Flexeril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cyclobenzaprine&reg;;",
"     </li>",
"     <li>",
"      Auro-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Ava-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Dom-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      JAMP-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Mylan-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Novo-Cycloprine;",
"     </li>",
"     <li>",
"      Nu-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      PHL-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      PMS-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Q-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      ratio-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Riva-Cycloprine;",
"     </li>",
"     <li>",
"      ZYM-Cyclobenzaprine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F155299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Skeletal Muscle Relaxant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F155280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Muscle spasm:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Do not use longer than 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release: Usual: 15 mg once daily; some patients may require up to 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, immediate release: Initial: 5 mg 3 times/day; may increase up to 10 mg 3 times/day if needed",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4844797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26709?source=see_link\">",
"      see \"Cyclobenzaprine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Muscle spasm:",
"     </b>",
"     Oral: Tablet, immediate release: Children &ge;15 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F155281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, extended release: Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, immediate release: Initial: 5 mg; titrate dose slowly and consider less frequent dosing",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F155282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Capsule, extended release: Mild-to-severe impairment: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Tablet, immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment: Initial: 5 mg;  use with caution; titrate slowly and consider less frequent dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate-to-severe impairment: Use not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amrix&reg;: 15 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 7.5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fexmid&reg;: 7.5 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flexeril&reg;: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5431329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Extended release capsules: Administer at the same time each day. Do not crush or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of muscle spasm associated with acute, painful musculoskeletal conditions",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10546765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of muscle spasm associated with acute temporomandibular joint pain (TMJ)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F155306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cyclobenzaprine may be confused with cycloSERINE, cyproheptadine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexeril&reg; may be confused with Floxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin: Brand name for cyclobenzaprine [Chile], but also the brand name for diclofenac [Argentina] and orphenadrine [Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin [Chile] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]; Fluoxine brand name for fluoxetine [Thailand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F155297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (29% to 39%), dizziness (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (21% to 32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (1% to 6%), headache (1% to 5%), confusion (1% to 3%), irritability (1% to 3%), mental acuity decreased (1% to 3%), nervousness (1% to 3%), somnolence (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (&le;4%), abdominal pain (1% to 3%), constipation (1% to 3%), diarrhea (1% to 3%), gastric regurgitation (1% to 3%), nausea (1% to 3%), unpleasant taste (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (1% to 3%), upper respiratory infection (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, arrhythmia, ataxia, dysarthria, hepatitis (rare), hypertonia, hypotension, paresthesia, psychosis, rash, seizures, syncope, tachycardia, tremor",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F155260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclobenzaprine or any component of the formulation; during or within 14 days of MAO inhibitors; hyperthyroidism; congestive heart failure; arrhythmias; heart block or conduction disturbances; acute recovery phase of MI",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F155245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Use with caution in patients with angle-closure glaucoma, increased intraocular pressure, or urinary frequency/hesitancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Toxicity: Cyclobenzaprine shares the toxic potentials of the tricyclic antidepressants, including prolongation of conduction time, arrhythmias, and tachycardia; the usual precautions of tricyclic antidepressant therapy should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild hepatic impairment; plasma concentrations increased twofold in presence of mild impairment. Not recommended in moderate-to-severe hepatic impairment. Extended release capsules not recommended in patients with hepatic impairment of any severity (mild, moderate, or severe).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Do not use concomitantly or within 14 days after MAO inhibitors; combination may cause hypertensive crisis and/or severe convulsions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Muscle relaxants are poorly tolerated by the elderly due to potent anticholinergic effects, sedation, and risk of fracture. Efficacy is questionable at dosages tolerated by elderly patients; avoid use (Beers Criteria). Extended release capsules not recommended for use in elderly.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F155293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Cyclobenzaprine may enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Cyclobenzaprine may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. Cyclobenzaprine may enhance the serotonergic effect of TraMADol. This could result in serotonin syndrome.  Management: Seek alternatives.  If these agents are given in combination, monitor for seizure activity and signs and symptoms of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F155273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Food increases bioavailability (peak plasma concentrations increased by 35% and area under the curve by 20%) of the extended release capsule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4844795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F155284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F155262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Amrix Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (60): $1437.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (60): $1437.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cyclobenzaprine HCl Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/g (60 g): $227.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Cyclobenzaprine Comfort Pac Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $74.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cyclobenzaprine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $164.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (1000): $3873.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $115.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Flexeril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $189.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $209.86",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F155263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Binelax ER (KP);",
"     </li>",
"     <li>",
"      Ciclamil (CN);",
"     </li>",
"     <li>",
"      Cycloflex (IL);",
"     </li>",
"     <li>",
"      Flexer (PE, TW);",
"     </li>",
"     <li>",
"      Flexiban (AR, IT, PT);",
"     </li>",
"     <li>",
"      Miosan (BR);",
"     </li>",
"     <li>",
"      Musgud (TW);",
"     </li>",
"     <li>",
"      Tensodox (EC, PE);",
"     </li>",
"     <li>",
"      Yuredol (MX);",
"     </li>",
"     <li>",
"      Yurelax (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F155244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Centrally-acting skeletal muscle relaxant pharmacologically related to tricyclic antidepressants; reduces tonic somatic motor activity influencing both alpha and gamma motor neurons",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F155259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4, 1A2, and 2D6; may undergo enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 33% to 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Range: 8-37 hours; Immediate release tablet: 18 hours; Extended release capsule: 32-33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Extended release capsule: 7-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as inactive metabolites); feces (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/60/13254/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heckerling PS and Bartow TJ, &ldquo;Paradoxical Diaphoresis in Cyclobenzaprine Poisoning,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1984, 101(6):881.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/60/13254/abstract-text/6497211/pubmed\" id=\"6497211\" target=\"_blank\">",
"        6497211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Theoharides TC, Harris RS, and Weckstein D, &ldquo;Neuroleptic Malignant-Like Syndrome Due to Cyclobenzaprine?&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1995, 15(1):79-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/60/13254/abstract-text/7714231/pubmed\" id=\"7714231\" target=\"_blank\">",
"        7714231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winchell GA, King JD, Chavez-Eng CM, et al, &ldquo;Cyclobenzaprine Pharmacokinetics, Including the Effects of Age, Gender, and Hepatic Insufficiency,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2002, 42(1):61-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/60/13254/abstract-text/11808825/pubmed\" id=\"11808825\" target=\"_blank\">",
"        11808825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong EC, Koenig J, and Turk J, &ldquo;Potential Interference of Cyclobenzaprine and Norcyclobenzaprine With HPLC Measurement of Amitriptyline and Nortriptyline: Resolution by GC-MS Analysis,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(4):218-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/60/13254/abstract-text/8531466/pubmed\" id=\"8531466\" target=\"_blank\">",
"        8531466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9306 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13254=[""].join("\n");
var outline_f12_60_13254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155277\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155299\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155280\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4844797\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155281\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795915\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155282\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155255\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155241\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5431329\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155257\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10546765\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155306\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155297\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155260\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155245\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155293\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155250\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155273\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155252\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4844795\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155284\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155262\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155263\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155244\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155259\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9306|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/23/33140?source=related_link\">",
"      Cyclobenzaprine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26709?source=related_link\">",
"      Cyclobenzaprine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_60_13255="Cecocolic rotation";
var content_f12_60_13255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Normal rotation of the cecocolic loop",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 561px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. The starting point of the cecum is directly inferior to the superior mesenteric artery (SMA). B. The cecum has rotated 90 degrees counterclockwise. C. The cecum continues to rotate around the SMA, now 180 degrees from its starting point and directly ventral to the SMA. D. The final position the cecum, after 270 degrees counterclockwise rotation, is to the right of the SMA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13255=[""].join("\n");
var outline_f12_60_13255=null;
var title_f12_60_13256="Overview of the evaluation and management of atrial flutter";
var content_f12_60_13256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the evaluation and management of atrial flutter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/60/13256/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/60/13256/contributors\">",
"     Robert Phang, MD, FACC, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/60/13256/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/60/13256/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/60/13256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/60/13256/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/60/13256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter is a relatively common arrhythmia that can be deleterious by impairing the cardiac output and by promoting atrial thrombus formation that can lead to systemic embolization. It is characterized by rapid, regular atrial depolarizations at a characteristic rate of approximately 300",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"   </p>",
"   <p>",
"    For",
"    many years, atrial flutter has been considered together with atrial fibrillation (AF). While some issues of therapy are the same, such as the restoration of sinus rhythm, the maintenance of sinus rhythm after cardioversion, slowing the ventricular rate, and prevention of systemic embolism, atrial flutter is quite distinct from atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional classification distinguishes two types of atrial flutter: type I (typical, common, or counterclockwise isthmus-dependent) and type II (atypical). These arrhythmias were differentiated by Wells et al in 1979 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/2\">",
"     2",
"    </a>",
"    ]. Type I was separated from type II on the basis of the flutter rate (240 to 340",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    compared to 340 to 440",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    in type II), the existence of an excitable gap, the ability to transiently entrain type I but not type II, and the observation that type II can change in a \"stepwise\" manner to type I.",
"   </p>",
"   <p>",
"    In 2001, the European Society of Cardiology and the North American Society of Pacing and Electrophysiology proposed a classification that takes into consideration both anatomic features and electrophysiologic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/3\">",
"     3",
"    </a>",
"    ]. Type I atrial flutter was classified as a macroreentrant atrial tachycardia, while type II atrial flutter was considered unclassified because the mechanisms are not fully understood.",
"   </p>",
"   <p>",
"    The Wells classification remains the most commonly used in the clinical literature and by clinicians.",
"   </p>",
"   <p>",
"    The two forms of atrial flutter have important electrophysiologic differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I or typical atrial flutter is a macroreentrant arrhythmia, in which a depolarizing stimulus (such as a single atrial ectopic beat) excites an area of the atrium and then travels sufficiently slowly in a pathway that is sufficiently long that there is an \"excitable gap,\" that is, an area behind the wave of depolarization that has recovered its excitability and can be reactivated, thereby forming a circuit. The slowly conducting reentrant circuit is located in the low right atrial isthmus. The isthmus is a path between the orifice of inferior vena cava and the annulus of the tricuspid valve (",
"      <a class=\"graphic graphic_figure graphicRef52904 \" href=\"UTD.htm?27/10/27811\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"       \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In typical type I flutter, the reentrant circuit usually has a counterclockwise rotation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/6\">",
"       6",
"      </a>",
"      ]. The counterclockwise rotation involves the direction of the activation wavefront within the right atrium with respect to the tricuspid valve annulus in the left anterior oblique projection (ie, activation proceeding up the intraatrial septum, superiorly over the roof of the right atrium, down the lateral wall and through the &ldquo;isthmus&rdquo; of atrial tissue between the inferior vena cava and the tricuspid valve annulus). Another form of typical flutter has the same isthmus-dependent features, the same anatomic barriers, and the same cycle length, but the reentrant circuit has a clockwise rotation. [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/3,7\">",
"       3,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type II or atypical atrial flutter is not isthmus-dependent, seems to lack an excitable gap, and cannot be entrained. It is thought that these characteristics result from an intraatrial reentrant circuit that is very short in contrast to the long isthmus in type I atrial flutter [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=see_link\">",
"       \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, physical examination, and specific laboratory and cardiologic testing are all part of the evaluation of the patient with atrial flutter. The minimum evaluation suggested by the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines for atrial fibrillation is largely appropriate for atrial flutter as well [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with recent onset atrial flutter have symptoms resulting from the rapid heart rate. Typical complaints include palpitations, fatigue, lightheadedness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild shortness of breath. Less common problems include significant dyspnea, angina, hypotension, presyncope, or infrequently, syncope. Embolic events are uncommon unless the patient has associated rheumatic heart disease, depressed left ventricular function, atrial fibrillation, or a history of thromboembolism.",
"   </p>",
"   <p>",
"    The purpose of the remainder of the history and of the physical examination is to define symptoms associated with atrial flutter; the onset or date of discovery of the arrhythmias as well as its frequency and duration; the precipitating causes and modes of termination; the previous response to drug therapy; and the presence of heart disease or potentially reversible causes.",
"   </p>",
"   <p>",
"    An effort should also be made to determine the cause of atrial flutter. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=see_link\">",
"     \"Atrial flutter: Epidemiology, classification, and risk factors\"",
"    </a>",
"    .) Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial flutter is unusual in the normal heart, and is especially uncommon in children or young adults.",
"     </li>",
"     <li>",
"      Atrial flutter is common in rheumatic heart disease (particularly if the mitral valve is involved), in diseases that produce left ventricular dysfunction, sick sinus syndrome, pericarditis, pulmonary embolism, chronic obstructive pulmonary disease, mitral valve prolapse, hyperthyroidism, and after cardiopulmonary bypass surgery even when atriotomy is not part of the procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"       \"Atrial fibrillation and flutter after cardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrial flutter can occur in patients with an atrial septal defect, presumably because the septal defect acts as an anatomical obstacle to normal conduction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"       \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to these associations, atrial flutter is a relatively uncommon complication of acute myocardial infarction and is rarely, if ever, a manifestation of digitalis toxicity. Furthermore, the diagnosis of atrial flutter may be difficult to establish when, as commonly occurs during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      therapy, the atrial flutter has a slow ventricular response, with a rate that overlaps that seen in other supraventricular tachycardias, such as nonparoxysmal atrial tachycardia with a 2:1 AV response due to digitalis intoxication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=see_link\">",
"       \"Supraventricular arrhythmias after myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"       \"Basic approach to arrhythmias due to digoxin toxicity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a population-based study in which there were 181 new cases of atrial flutter, 16 percent were attributable to heart failure and 12 percent to chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/9\">",
"     9",
"    </a>",
"    ]. Atrial flutter without an identifiable predisposing factor (\"lone\" atrial flutter) occurred in 1.7 percent. The incidence increased markedly with age, ranging from 5 per 100,000 person years under age 50 to 587 per 100,000 person years over age 80.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram is used to verify the presence or absence of AF; determine typical versus atypical mechanism by examining P wave morphology and cycle length; identify left ventricular hypertrophy, preexcitation, bundle branch block, or prior MI; to assess for other atrial arrhythmias on earlier ECGs; and to measure important intervals such as the RR, QRS, and QT, which may reflect genetic abnormalities or the effects of drug therapy.",
"   </p>",
"   <p>",
"    There is typically 2:1 conduction across the atrioventricular (AV) node; as a result, the ventricular rate is usually one-half the flutter rate in the absence of AV node dysfunction. Even",
"    <span class=\"nowrap\">",
"     input/output",
"    </span>",
"    ratios (eg, 2:1 or 4:1 conduction) are much more common than odd ratios (eg, 3:1 or 5:1). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .) Odd ratios probably reflect bilevel block in the AV node. On the other hand, a 1:1 response suggests catecholamine excess, parasympathetic withdrawal, the presence of antiarrhythmic drug therapy with Class IA or IC agents (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ), or the existence of an accessory bypass tract in the preexcitation syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;When clinical findings suggest, the chest x-ray may be useful in assessing the lungs, vasculature, and cardiac outline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transthoracic echocardiogram is performed to evaluate the size of the right and left atria and the size and function of the right and left ventricles; to detect possible valvular heart disease, left ventricular hypertrophy, and pericardial disease; and to assess peak right ventricular pressure. Thrombus in the left atrium, most often the left atrial appendage, is unusual in stable atrial flutter because of the regular atrial contractions, but it is often uncertain whether the patient also has atrial fibrillation.",
"   </p>",
"   <p>",
"    Transthoracic echocardiography has a low sensitivity for detecting thrombus, and transesophageal echocardiography (TEE) is preferred for this purpose. TEE may play an important role in the selection of patients for cardioversion as it does in atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Additional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing is often useful to reproduce exercise-induced atrial fibrillation and to evaluate for associated ischemic heart disease. Identifying underlying coronary disease is particularly important if a class IC antiarrhythmic drug is used since, as demonstrated in the CAST trial, these drugs have a significant proarrhythmic effect and increase mortality in such patients&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/10\">",
"     10",
"    </a>",
"    ], and by their enhanced AV nodal conduction properties, raise the risk of rapidly conducted atrial flutter (1:1 conduction).",
"   </p>",
"   <p>",
"    Holter monitoring or event recorders are used to identify the arrhythmia if symptoms are nonspecific, to identify triggering events, and to detect associated atrial arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrophysiological studies may be required for diagnosis, mapping pathways, and therapeutic ablation. Serum electrolytes and pulmonary and thyroid function tests should be ordered if appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEMODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike atrial fibrillation, there is active atrial contraction during atrial flutter. Nevertheless, there are a number of hemodynamic changes that occur with atrial flutter, including an increase in the mean right and left atrial pressures, a reduction in right and left ventricular end-diastolic pressures, a decrease in systolic blood pressure and an increase in diastolic pressure; the cardiac index is generally unaltered [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/11\">",
"     11",
"    </a>",
"    ]. The reduction in left ventricular pressure is a result of the rapid heart rate, while the increase in atrial pressure is due, in part, to contraction against closed atrioventricular valves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As is true for atrial fibrillation, there are four major issues that must be addressed in the treatment of atrial flutter:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reversion to normal sinus rhythm (NSR)",
"     </li>",
"     <li>",
"      Maintenance of NSR",
"     </li>",
"     <li>",
"      Control of the ventricular rate in patients",
"     </li>",
"     <li>",
"      Prevention of systemic embolization, particularly in the patient who also has atrial fibrillation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following discussion will provide a brief summary of these four treatment issues, each of which is discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Reversion to NSR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard approaches to converting atrial flutter to sinus rhythm are synchronized internal or external DC cardioversion or pharmacologic cardioversion with class IA (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    ), class IC (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ), or class III antiarrhythmic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ). DC cardioversion is indicated in patients who are hemodynamically unstable, while either medical or electrical cardioversion can be performed in stable patients in whom spontaneous reversion due to correction of an underlying disease is not likely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Entrainment and pacing is another method to convert atrial flutter to sinus rhythm. The most frequent settings for this approach are patients with preexisting permanent pacemakers where overdrive pacing can be performed via the programmer, and following cardiac surgery when pacing via the temporary epicardial [atrial] wire can be performed. Of course, the usual precautions should be taken with regard to preparatory anticoagulation or TEE, if the duration of atrial flutter is beyond 48 hours or of unknown duration.",
"   </p>",
"   <p>",
"    In the hemodynamically stable patient, watchful waiting may be sufficient since atrial flutter is usually an unstable rhythm that generally reverts spontaneously to normal sinus rhythm in days to weeks. As in atrial fibrillation, the best candidate has a left atrial size less than 4.5 to 5 cm, atrial flutter of recent onset, little or no heart failure, and an underlying reversible cause such as hyperthyroidism, myocardial infarction, and pulmonary embolism.",
"   </p>",
"   <p>",
"    If pharmacologic reversion is deemed necessary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    , which is approved by the Food and Drug Administration only for intravenous use, is the drug of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/1\">",
"     1",
"    </a>",
"    ]. It can revert atrial flutter to a sinus mechanism in approximately 60 percent of patients and is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/1,6,12\">",
"     1,6,12",
"    </a>",
"    ]. Ibutilide therapy carries a risk of QT prolongation and torsades de pointes. One report noted an 8.3 percent incidence of torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/13\">",
"     13",
"    </a>",
"    ]. Although the arrhythmia is usually not sustained because of the short-half life of ibutilide, cardioversion was required for sustained arrhythmia in 1.7 percent. As a result, the use of ibutilide requires continuous monitoring, resuscitative equipment including a defibrillator, and personnel trained in the use of electrical cardioversion and resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=see_link\">",
"     \"Therapeutic use of ibutilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rate control with an AV nodal blocker with a calcium channel blocker (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ), beta blocker, or, if the patient has heart failure or hypotension,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    should be attained before instituting class IA and IC drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) because of possible recurrence with atrial flutter and a very rapid ventricular rate. Long-term therapy with one of these drugs may be required in the event of atrial fibrillation that may appear, even after ablative cure of the atrial flutter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maintenance of NSR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of recurrence of atrial flutter is difficult to determine because most published data combine atrial flutter with atrial fibrillation. However, the recurrence rate is substantial, perhaps 50 percent at one year. In one report, for example, 50 patients were followed for a mean of 3.5 years after cardioversion for chronic atrial flutter; prophylactic antiarrhythmic drugs were not given [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/14\">",
"     14",
"    </a>",
"    ]. Sinus rhythm was maintained at six months and five years in 53 and 42 percent of patients, respectively. Using a protocol of repeated cardioversion (median of two per patient), sinus rhythm at five years was maintained in 45 patients, although 16 patients required chronic antiarrhythmic drug therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pharmacologic strategies, as with atrial fibrillation, are to depress initiating atrial premature beats, which may require the use of class IA and IC drugs, beta blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and to prolong the atrial refractory period with class III drugs. Amiodarone is often used since, in addition to helping maintain normal sinus rhythm, it also helps control the ventricular response if atrial fibrillation or atrial flutter occurs.",
"   </p>",
"   <p>",
"    However, because of the high rate of recurrence in patients without a correctable cause, and because of the high success rate with radiofrequency ablation, ablation is generally preferable to long-term pharmacologic therapy in patients with type I (typical) atrial flutter. The isthmus between the inferior vena cava and the tricuspid annulus (IVC-TA isthmus) is an obligatory route for type I flutter, and, as such, is the preferred anatomic target for ablation (",
"    <a class=\"graphic graphic_figure graphicRef52904 \" href=\"UTD.htm?27/10/27811\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The potential efficacy of this approach was illustrated in a report from the NASPE Prospective Catheter Ablation Registry in which 477 patients underwent ablation of the IVC-TA isthmus for atrial flutter: acute success was achieved in 86 percent, with a recurrence rate of 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/15\">",
"     15",
"    </a>",
"    ]. Recurrence is often with type II (atypical) atrial flutter or atrial fibrillation.",
"   </p>",
"   <p>",
"    Successful outcomes with ablation can also be achieved in patients with type II atrial flutter, although the experience is more limited [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H26#H26\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'Left atrial flutter'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link&amp;anchor=H2#H2\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rate control in chronic atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rate control in chronic atrial flutter, as in atrial fibrillation, usually involves the administration of a calcium channel blocker, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    or a beta blocker.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is used less often because its major action is an enhancement of vagal tone, which is offset during exertion. The main indication is concurrent heart failure in which it is often given in combination with another drug that decreases AV nodal conduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=see_link\">",
"     \"Control of ventricular rate in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ablative therapy of the AV node is rarely indicated unless the atrial flutter is resistant to ablation or antiarrhythmic drugs or is associated with atrial fibrillation in which the ventricular response cannot be controlled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prevention of systemic embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients have periods of atrial flutter associated with episodes or a history of atrial fibrillation. In such individuals, the embolic risk is similar to that in patients with atrial fibrillation and the choice between oral anticoagulation and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy is based upon perceived embolic risk&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H23#H23\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Specific patient groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for embolization in addition to atrial fibrillation include rheumatic heart disease, depressed left ventricular systolic function, a history of thromboembolism, and atypical atrial flutter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chronic atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained atrial flutter is an unusual arrhythmia, but such patients are at some embolic risk. The frequency with which this might occur and the importance of anticoagulation was illustrated in a report of 100 patients who were referred to an electrophysiology laboratory for cardioversion of atrial flutter that was present for at least six months: 13 patients had a thromboembolic event that was attributable to atrial flutter in six [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/19\">",
"     19",
"    </a>",
"    ]. The event occurred during atrial flutter or after cardioversion and none of the patients were receiving adequate anticoagulation. There were no embolic events in patients on adequate anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=see_link&amp;anchor=H5#H5\">",
"     \"Embolic risk and the role of anticoagulation in atrial flutter\", section on 'Embolic risk in chronic atrial flutter'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One problem with interpreting these data is that many patients with chronic atrial flutter also have periods of atrial fibrillation. This is an important issue since, in a review of the Medicare database, the risk of stroke was increased in patients with atrial flutter who also had atrial fibrillation (to the same degree as in patients with atrial fibrillation alone), while those with isolated atrial flutter had a stroke risk equivalent to the control population (",
"    <a class=\"graphic graphic_figure graphicRef67382 \" href=\"UTD.htm?22/12/22734\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimal management is also unclear in patients with lone atrial flutter who have no identifiable predisposing factor. Patients with lone atrial fibrillation are at low embolic risk (approximately 0.3 percent per year in younger patients and 0.9 percent per year over the age of 60) and are generally treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . However, the thromboembolic risk may be higher in patients with lone atrial flutter, particularly those with controlled hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/21\">",
"     21",
"    </a>",
"    ]. It has been recommended that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy should be considered in such patients who are over age 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Relation to cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the embolic risk after cardioversion. In two large series of patients with atrial flutter in the apparent absence of atrial fibrillation, the incidence of postcardioversion embolic events was 0.6 and 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Higher values have been described in patients who also have a history of atrial fibrillation or underlying heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the data were not conclusive, a number of these reports found no embolic events in patients who were adequately anticoagulated prior to cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines published in 2008 from the American College of Chest Physicians on antithrombotic therapy in atrial fibrillation and in 2006 from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    recommend that consideration be given to managing anticoagulation during cardioversion of atrial flutter in a manner similar to that for AF&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/8,26\">",
"     8,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our recommendations for anticoagulation in patients with atrial flutter who are to undergo cardioversion are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients presenting with an initial episode of atrial flutter should have a transthoracic echocardiogram to evaluate for possible rheumatic mitral valve disease and to assess left ventricular systolic function.",
"     </li>",
"     <li>",
"      Patients with atrial flutter who have rheumatic heart disease, depressed left ventricular systolic function, a history of thromboembolism, atypical atrial flutter, or a prior history of atrial fibrillation are at increased risk for atrial thrombus formation and are best treated conservatively with three to four weeks of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      prior to cardioversion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/23\">",
"       23",
"      </a>",
"      ]. The goal INR is 2.0 to 3.0. It has been suggested that it may be prudent to aim for a minimum INR of 2.5 before cardioversion or documentation that the INR has consistently been &ge;2.0 in the weeks before cardioversion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13256/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another option, which has been evaluated in patients with atrial fibrillation, is TEE-guided early cardioversion with the use of short-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    at the time of TEE and continued for four weeks after cardioversion. The safety of this approach has not been formally studied in atrial flutter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in patients with atrial fibrillation, cardioversion can be safely performed if the arrhythmia duration is less than 48 hours",
"      <strong>",
"       and",
"      </strong>",
"      the patient has no high-risk features (eg, rheumatic heart disease, depressed left ventricular function, or a history of thromboembolism). Although long-term anticoagulation is not recommended following a defined episode of less than 48 hours, risk factors for developing atrial flutter and atrial fibrillation may increase the risk of recurrence, and close clinical follow-up is recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link&amp;anchor=H16#H16\">",
"       \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'AF of less than 48 hours duration'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=see_link\">",
"       \"Patient information: Atrial flutter (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11099516\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial flutter is characterized by very organized atrial activity on the electrocardiogram, which underlies its stable cycle length and underlying mechanism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation, rate-control medication treatment, and anticoagulation strategies for prevention of systemic thromboembolism are similar to those used for atrial fibrillation. However, long-term antiarrhythmic medications are infrequently used given the high rate of success of ablation for typical atrial flutter. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'General treatment issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical form (Type I) of atrial flutter has a very well understood and defined mechanism within the right atrium, which provides a target for radiofrequency ablation with a high rate of success. The atypical form (Type II) has a variable location within either the right or left atrium, and a lower success rate with ablation treatment. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Maintenance of NSR'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/1\">",
"      Wellens HJ. Contemporary management of atrial flutter. Circulation 2002; 106:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/2\">",
"      Wells JL Jr, MacLean WA, James TN, Waldo AL. Characterization of atrial flutter. Studies in man after open heart surgery using fixed atrial electrodes. Circulation 1979; 60:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/3\">",
"      Saoudi N, Cos&iacute;o F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/4\">",
"      Tai CT, Chen SA, Chiang CE, et al. Characterization of low right atrial isthmus as the slow conduction zone and pharmacological target in typical atrial flutter. Circulation 1997; 96:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/5\">",
"      Kalman JM, Olgin JE, Saxon LA, et al. Activation and entrainment mapping defines the tricuspid annulus as the anterior barrier in typical atrial flutter. Circulation 1996; 94:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/6\">",
"      Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/7\">",
"      Kalman JM, Olgin JE, Saxon LA, et al. Electrocardiographic and electrophysiologic characterization of atypical atrial flutter in man: use of activation and entrainment mapping and implications for catheter ablation. J Cardiovasc Electrophysiol 1997; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/8\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/9\">",
"      Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/10\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/11\">",
"      Alboni P, Scarf&ograve; S, Fuc&agrave; G, et al. Atrial and ventricular pressures in atrial flutter. Pacing Clin Electrophysiol 1999; 22:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/12\">",
"      Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation 1997; 96:4298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/13\">",
"      Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/14\">",
"      Crijns HJ, Van Gelder IC, Tieleman RG, et al. Long-term outcome of electrical cardioversion in patients with chronic atrial flutter. Heart 1997; 77:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/15\">",
"      Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/16\">",
"      Ja&iuml;s P, Shah DC, Ha&iuml;ssaguerre M, et al. Mapping and ablation of left atrial flutters. Circulation 2000; 101:2928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/17\">",
"      Marrouche NF, Natale A, Wazni OM, et al. Left septal atrial flutter: electrophysiology, anatomy, and results of ablation. Circulation 2004; 109:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/18\">",
"      Kilicaslan F, Verma A, Yamaji H, et al. The need for atrial flutter ablation following pulmonary vein antrum isolation in patients with and without previous cardiac surgery. J Am Coll Cardiol 2005; 45:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/19\">",
"      Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol 1997; 30:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/20\">",
"      Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. Am J Cardiol 2001; 87:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/21\">",
"      Silverman DI, Manning WJ. Prophylactic anticoagulation of atrial flutter prior to cardioversion: meeting the \"burden of proof\". Am J Med 2001; 111:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/22\">",
"      Halligan SC, Gersh BJ, Brown RD Jr, et al. The natural history of lone atrial flutter. Ann Intern Med 2004; 140:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/23\">",
"      Elhendy A, Gentile F, Khandheria BK, et al. Thromboembolic complications after electrical cardioversion in patients with atrial flutter. Am J Med 2001; 111:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/24\">",
"      Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002; 40:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/25\">",
"      Seidl K, Hauer B, Schwick NG, et al. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 1998; 82:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/26\">",
"      Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13256/abstract/27\">",
"      Olshansky B. High intensity anticoagulation for cardioversion of atrial arrhythmias? The shocking truth. J Am Coll Cardiol 2002; 40:934.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1048 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13256=[""].join("\n");
var outline_f12_60_13256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11099516\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Additional testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEMODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENERAL TREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Reversion to NSR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maintenance of NSR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rate control in chronic atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prevention of systemic embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chronic atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Relation to cardioversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11099516\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1048\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1048|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/10/27811\" title=\"figure 1\">",
"      Flutter circuit right atrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/12/22734\" title=\"figure 2\">",
"      Atrial flutter stroke risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1048|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=related_link\">",
"      Atrial flutter: Epidemiology, classification, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=related_link\">",
"      Control of ventricular rate in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=related_link\">",
"      Embolic risk and the role of anticoagulation in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=related_link\">",
"      Maintenance of sinus rhythm after cardioversion in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=related_link\">",
"      Patient information: Atrial flutter (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=related_link\">",
"      Restoration of sinus rhythm in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=related_link\">",
"      Therapeutic use of ibutilide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_60_13257="Basic case 2 with answer";
var content_f12_60_13257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Complete RBBB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing characteristic changes in the precordial leads in complete RBBB. The asynchronous activation of the two ventricles increases the QRS duration (0.13 sec). The terminal forces are rightward and anterior due the delayed activation of the right ventricle, resulting in an rsR' pattern in the anterior-posterior lead V1 and a wide negative S wave in the left-right lead V6 (and, not shown, in lead I).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13257=[""].join("\n");
var outline_f12_60_13257=null;
var title_f12_60_13258="IgG subclass deficiency";
var content_f12_60_13258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   IgG subclass deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/60/13258/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/60/13258/contributors\">",
"     J Keith Lemmon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/60/13258/contributors\">",
"     Alan P Knutsen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/60/13258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/60/13258/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/60/13258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/60/13258/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/60/13258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term IgG subclass deficiency refers to a significant decrease in the serum concentrations of one or more subclasses of IgG in a patient whose total IgG concentration is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/1\">",
"     1",
"    </a>",
"    ]. It is a laboratory finding that does not necessarily equate to a clinical disorder, since up to 20 percent of the population have subnormal levels of one or more subclasses [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis of a clinically significant IgG subclass deficiency requires evidence of antibody dysfunction, in the form of recurrent infections and an inadequate response to vaccine challenge.",
"   </p>",
"   <p>",
"    The clinical presentation, pathogenesis, diagnosis, and treatment of IgG subclass deficiency are presented here. The physical and biological properties of IgG subclasses are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=see_link\">",
"     \"IgG subclasses: Physical properties, genetics, and biologic functions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal ranges have been generated from healthy populations and defined as mean levels &plusmn; two standard deviations, which includes 95 percent of individuals. The remaining 5 percent have levels below or above this range. Thus, by definition, IgG subclasses are low in approximately 2.5 percent of the population. However, the normal ranges for IgG subclasses are broad, and vary with the age of the population studied, presence or absence of disease, and the method of analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/3-10\">",
"     3-10",
"    </a>",
"    ]. In some studies, up to 20 percent of the general population had significantly lower levels of one or more of the IgG subclasses, a finding that has fueled ongoing debate about whether or not IgG subclass deficiency truly represents a primary immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/2\">",
"     2",
"    </a>",
"    ]. Because of this inherent variability, the absolute levels of IgG subclasses, especially IgG2, should always be correlated with antibody responses to vaccines.",
"   </p>",
"   <p>",
"    The prevalence of IgG subclass deficiency was indirectly estimated in a study that measured the frequency of homozygous gene deletions in 11,000 healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/8\">",
"     8",
"    </a>",
"    ]. From the observed frequency of the homozygous genotype, the investigators calculated that 1 to 3 percent of healthy individuals should be heterozygous for multiple heavy-chain gene deletion. Since this study included IgA and IgE deletions, the proportion of healthy individuals with IgG subclass deficiency would be lower.",
"   </p>",
"   <p>",
"    Other observations about IgG subclass levels include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with adults, children have lower levels of IgG2. In one study, IgG2 was decreased in 19 percent of 3854 healthy children (",
"      <a class=\"graphic graphic_table graphicRef66552 \" href=\"UTD.htm?39/61/40923\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/11\">",
"       11",
"      </a>",
"      ]. In addition, IgG2 levels rise to adult levels more slowly than do other subclasses. IgG2 levels are 20 percent of adult levels at one year of age, 50 percent at five years of age, and 75 percent at 14 years of age. In contrast, IgG1 and IgG3 reach adult levels more rapidly, being about 50 percent by one year of age, and 75 percent by five years of age.",
"     </li>",
"     <li>",
"      IgG subclass deficiency is a common finding in patient populations with increased susceptibility to infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In two large series from France, IgG subclass deficiency was detected in 21 percent of 483 patients with abnormally frequent, prolonged, or severe infections who had been recruited from clinical immunology, pediatrics, and infectious diseases departments [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/6,10\">",
"       6,10",
"      </a>",
"      ]. IgG3 was the most frequently deficient subclass, which has also been observed in other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/3-5,12\">",
"       3-5,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of 1175 adults with symptoms suggestive of an antibody defect, decreased IgG1, IgG2, IgG3, and IgG4 levels were noted in 28, 17, 13, and 9 percent, respectively (",
"      <a class=\"graphic graphic_table graphicRef66552 \" href=\"UTD.htm?39/61/40923\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sex distribution of IgG subclass deficiency differs in children and adults. IgG subclass deficiencies are more common in boys by a ratio of 3:1 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. In contrast, there is a predominance of females after age 16. This shift in sex distribution may be due to hormonal influences upon the development and maturation of the immune system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG subclass deficiency may be asymptomatic or associated with recurrent infections and a heterogeneous group of related disorders. Interpretation of the available medical literature is complicated by the fact that many series have considered both asymptomatic and symptomatic patients together. Early studies (beginning in the 1970s) of patients with recurrent infections did not routinely assess antibody function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6410636\">",
"    <span class=\"h2\">",
"     Asymptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals lacking one or more IgG subclasses are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/14-21\">",
"     14-21",
"    </a>",
"    ]. In addition, there are patients with complete deficiencies of multiple subclasses (combinations of IgG1, IgG2, IgG4, IgE, or IgA), who remain healthy and free of infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6410643\">",
"    <span class=\"h2\">",
"     Symptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic IgG subclass deficiency most commonly present with recurrent sinopulmonary infections. The infections vary in frequency and severity, and include otitis, sinusitis, and pneumonia that are usually due to common respiratory bacterial pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/1,18,19,26\">",
"     1,18,19,26",
"    </a>",
"    ]. More serious infections that can occur include osteomyelitis, meningitis, septicemia, diarrhea, and various skin infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     IgG1 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG1 subclass deficiency usually results in generalized hypogammaglobulinemia, since IgG1 normally comprises almost two-thirds of the total serum IgG. Thus, most patients with significant IgG1 deficiency are classified as common variable immunodeficiency (CVID), a diagnosis that also requires decreased levels of IgA, IgM, or both. Selective IgG1 deficiency with normal total IgG is uncommon. It occasionally occurs if there are concomitant elevations in IgA or IgM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=see_link\">",
"     \"IgG subclasses: Physical properties, genetics, and biologic functions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgG1 is often associated with other subclass deficiencies, especially IgG3 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/13\">",
"     13",
"    </a>",
"    ]. It is usually seen in adults and may appear first in patients who subsequently develop CVID. When present in young children, it often represents resolving transient hypogammaglobulinemia of infancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=see_link\">",
"     \"Transient hypogammaglobulinemia of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic IgG1 deficiency is associated with susceptibility to pyogenic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/13\">",
"     13",
"    </a>",
"    ]. In a large study, selective IgG1 deficiency was detected in 119 of 3005 patients (4 percent) with frequent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repeated infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/27\">",
"     27",
"    </a>",
"    ]. These patients, predominately adults, had low IgG1 levels with normal levels of the other IgG subclasses, IgM, and IgA, thus excluding the diagnosis of CVID. Approximately 80 percent suffered from recurrent, predominately sinopulmonary infections, and 20 percent had asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     IgG2 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG2 subclass deficiency is more prevalent among children than adults, and is one of the most frequently identified disorders in children with recurrent infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. It has been described both as an isolated finding and in combination with IgG4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgA deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IgG2 is predominantly responsible for the antibody response against polysaccharide capsular antigens. As a result, IgG2 deficient patients are at increased risk for infections with Streptococcus pneumoniae, Haemophilus influenzae type b (Hib), and Neisseria meningitidis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Sinopulmonary infections, including sinusitis, otitis, and bronchitis predominate. However, more severe infections, such as pneumonia and meningococcemia, also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Obstructive lung disease and bronchiectasis have been reported with long-standing disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgG2 subclass deficiency has been reported in association with a variety of disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune disorders, including systemic lupus erythematosus, juvenile diabetes mellitus, primary Sj&ouml;gren's syndrome, autoimmune cytopenias, and vasculitides such as Henoch-Sch&ouml;nlein syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/36-39\">",
"       36-39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other primary immunodeficiencies, including ataxia-telangiectasia, defects in the production of interferon-gamma, and chronic mucocutaneous candidiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]. In children, an association has been reported among selective antibody deficiency, IgG2 subclass deficiency, and mannose-binding lectin (MBL) deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"       \"Inherited disorders of the complement system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=see_link\">",
"       \"Mannose-binding lectin deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"       \"Ataxia-telangiectasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link\">",
"       \"Chronic mucocutaneous candidiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary immunodeficient states, such as HIV-infection and allogeneic bone marrow transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several other disorders, including cystic fibrosis, severe H1N1 influenza, growth hormone deficiency, febrile seizures, Hodgkin lymphoma, and allergic colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/46-53\">",
"       46-53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pediatric IgG2 deficiency usually resolves with age although, in a minority of patients, it persists or progresses to CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/54\">",
"     54",
"    </a>",
"    ]. The course of IgG2 deficiency was evaluated in a retrospective analysis of 120 children aged greater than two years with recurrent infections and failure to respond to a majority of serotypes after Streptococcus pneumoniae immunization with the polysaccharide vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/55\">",
"     55",
"    </a>",
"    ]. IgG2, IgA, and IgA-IgG2 deficiency were identified in 19, 11, and 3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/55\">",
"     55",
"    </a>",
"    ]. After three years, immunoglobulin concentrations and polysaccharide responses had normalized in 87 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     IgG3 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG3 subclass deficiency is more common in adults than children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/4\">",
"     4",
"    </a>",
"    ]. It may occur alone or in combination with other subclass deficiencies, especially IgG1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. IgG3 is responsible for the immune response against Moraxella catarrhalis and to the M component of Streptococcus pyogenes, and these organisms are frequently implicated in infections in IgG3 deficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, patients with symptomatic IgG3 deficiency commonly suffer from the same types of recurrent sinopulmonary infections as those with other subclass deficiencies. Antibody responses to polysaccharide antigens may be normal or impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/5,19,59\">",
"     5,19,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asthma, chronic bronchitis, gastrointestinal infections, and recurrent lymphocytic meningitis have also been reported in patients with IgG3 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/5,6,19,59,60\">",
"     5,6,19,59,60",
"    </a>",
"    ]. Case reports note associations with diabetes mellitus type I, Henoch-Sch&ouml;nlein syndrome, recurrent herpes simplex infection, recurrent erysipelas, and C2 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/5,57\">",
"     5,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     IgG4 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG4 deficiency is believed to be common in the general population and the majority of affected people are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/2\">",
"     2",
"    </a>",
"    ]. IgG4 subclass deficiency has been described alone, in combination with IgG2 deficiency, and with IgA-IgG2 deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/15,29,61\">",
"     15,29,61",
"    </a>",
"    ]. Recurrent pulmonary infections and bronchiectasis are reported in symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/21,61-63\">",
"     21,61-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IgG4 deficiency has been reported in association with various other disorders, including ataxia-telangiectasia, chronic mucocutaneous candidiasis, growth hormone deficiency, allergic colitis, and Down's Syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/42,45,50,51,57,64\">",
"     42,45,50,51,57,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22337729\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG subclass deficiencies, as a group, are reported in conjunction with other primary immunodeficiency syndromes, atopic disorders, and autoimmunity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG subclass deficiencies are most strongly associated with IgA deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/65\">",
"       65",
"      </a>",
"      ]. Approximately 15 percent of IgA deficient patients also have IgG subclass deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/29,66\">",
"       29,66",
"      </a>",
"      ]. Associations have also been reported between IgG subclass deficiency and ataxia-telangiectasia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=see_link\">",
"       \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"       \"Ataxia-telangiectasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IgG subclass deficiency has also been documented in patients with atopic disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study of Brazilian children with severe asthma, the frequency of IgG subclass deficiency was 58 percent. There was no difference in frequency between subsets with or without recurrent infections [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There may be an association with food allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/3,55\">",
"       3,55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG subclass deficiency is associated with autoimmune conditions, such as vasculitis and cytopenias, and epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/36,67,68\">",
"       36,67,68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3396155\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary mechanisms underlying IgG subclass deficiency are unclear. Gene deletions, transcription errors, cytokine dysregulation, and allotypic variations are some mechanisms that have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Gene deletions",
"      </strong>",
"      : Heterozygous gene deletions result in reduced serum levels of the corresponding subclass. Deletions have been described for genes C&gamma;1, C&gamma;2, and C&gamma;4, although not C&gamma;3 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/69\">",
"       69",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Rare homozygous gene deletions, resulting in the complete absence of a subclass, have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/70\">",
"       70",
"      </a>",
"      ]. Homozygous deletions of large portions of the immunoglobulin heavy-chain gene, resulting in the absence of multiple immunoglobulin classes, are also described. Such patients may have no detectable IgG1, IgG2, IgG4, IgA1, or IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. Such deletions are thought to arise from unequal cross-over, resulting from extensive homology among the immunoglobulin heavy-chain genes on chromosome 14.",
"     </li>",
"     <li>",
"      <strong>",
"       Transcription errors",
"      </strong>",
"      : The mechanism of germline transcription may be negatively altered in a significant number of patients with IgG4 subclass deficiency. Restriction fragment length polymorphisms (RFLP) 5' of the S&gamma;4 loci within the &gamma; chain constant region gene complex have been specifically documented in patients with IgG4 deficiency patients compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cytokine dysregulation",
"      </strong>",
"      : Defective IFN-&gamma; production has been reported in IgG2 subclass deficiency, although its role in the pathogenesis of IgG2 subclass deficiency remains to be defined [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/74\">",
"       74",
"      </a>",
"      ]. Cytokines influence isotype switching in B cells through the regulation of germline transcription. IFN-&gamma;, released by antigen-activated CD4+ TH1 cells, serves as the main inducer of B cell switching to the IgG subclasses [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"       \"Immunoglobulin genetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Effect of allotype",
"      </strong>",
"      : Some IgG subclass deficiencies appear to be influenced by allotype. A lack of the G2m(n) allotype was demonstrated in both IgG2-deficient and IgG3-deficient Caucasian patients, and homozygosity for the G3m(g) and G3m(b) allotypes was found in IgG3 deficient patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/56,76\">",
"       56,76",
"      </a>",
"      ]. The genes that encode the IgG subclasses, as well as the influence of allotype on subclass levels and allotype nomenclature, are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=see_link&amp;anchor=H3#H3\">",
"       \"IgG subclasses: Physical properties, genetics, and biologic functions\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IgG subclass deficiency most commonly present with recurrent sinopulmonary infections. An initial approach to patients with recurrent infections, including key aspects of the clinical history and physical exam, is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=see_link&amp;anchor=H8541628#H8541628\">",
"     \"Approach to the adult with recurrent infections\", section on 'What is an excessive number of infections?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=see_link&amp;anchor=H8541386#H8541386\">",
"     \"Approach to the adult with recurrent infections\", section on 'Defects in immunoglobulins and/or complement proteins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1701973\">",
"    <span class=\"h2\">",
"     Initial laboratories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of patients with possible defects in humoral immunity includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete blood count and differential",
"     </li>",
"     <li>",
"      Total IgG, IgA, IgM levels",
"     </li>",
"     <li>",
"      Total hemolytic complement (CH50)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the results of these laboratories are normal, the diagnosis of IgG subclass deficiency can be considered in a patient with a suggestive clinical history.",
"   </p>",
"   <p>",
"    Further evaluation involves measurement of IgG subclass levels and assessment of the patient's responses to past infections and vaccination. Some experts suggest measuring IgG subclass levels",
"    <strong>",
"     only after",
"    </strong>",
"    demonstrating impaired responsiveness to vaccines, particularly polysaccharide vaccines. The rationale for this approach is that patients with adequate vaccine responses are treated the same as normals, even if a subclass deficiency is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1701937\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an immunology specialist is indicated for patients with recurrent sinopulmonary infections and either normal or abnormal results to the initial screening laboratory tests mentioned above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1701610\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a",
"    <strong>",
"     clinically significant",
"    </strong>",
"    IgG subclass deficiency is based upon two components [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The laboratory finding of deficiency of one or more IgG subclasses, typically to levels less than two standard deviations below the age-specific mean, in the presence of normal or near-normal total serum IgG concentrations. These levels should be assessed on at least two occasions while the patient is free of acute infections, using methods that are capable of detecting values in the very low ranges (ie, 1 to 8",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Measurement techniques and normal levels'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The demonstration of an inadequate response to vaccine challenge. Vaccine challenge is reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"       \"Assessing the immunologic response to vaccination\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Measurement techniques and normal levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different methods are used for the quantitative determination of IgG subclasses, which include radial immunodiffusion (RID), nephelometry, radioimmune assay (RIA), and enzyme-linked immunosorbent assay (ELISA). IgG subclass standard sera is calibrated against IgG subclass levels in WHO reference serum",
"    <span class=\"nowrap\">",
"     67/97.",
"    </span>",
"    ELISA is the most sensitive technique with detection range in the",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    range, whereas the sensitivity for RID and nephelometry is in the",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    range. Thus, measurement of IgG4 levels, which are lower than those of the other subclasses, is more accurately determined by ELISA. Inter-assay and intra-assay variations are minimal by nephelometry and RID but greater by ELISA. Agreement of IgG subclass levels in one serum sample is generally good comparing the different techniques. Low IgG subclass concentrations should be confirmed on at least one other occasion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG subclass levels change rapidly from birth to two years of age (",
"      <a class=\"graphic graphic_figure graphicRef58666 \" href=\"UTD.htm?30/0/30734\">",
"       figure 1",
"      </a>",
"      ). The data used to generate normal ranges are relatively limited, and laboratories performing IgG subclass determinations have rarely established normal ranges using their own assays (",
"      <a class=\"graphic graphic_table graphicRef50967 \" href=\"UTD.htm?6/48/6925\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Using radial immunodiffusion, IgG4 levels between 1 and 8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      are often reported as undetectable, thus increasing the frequency of this deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/2\">",
"       2",
"      </a>",
"      ]. Solid-phase enzyme-linked immunosorbent assays (ELISA) using specific monoclonal antibodies are more precise, and should be employed where available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Assessing function of IgG subclasses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing the function of IgG subclasses involves examination of a patient's response to previous vaccinations and infections. The patient's age, clinical history, and vaccination history must be taken into account. Antibody responses to both protein and polysaccharide antigens should be assessed in any patient suspected of having a clinically significant IgG subclass deficiency. The steps in assessing vaccine response are reviewed briefly here and in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18031031\">",
"    <span class=\"h3\">",
"     Measure baseline immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in evaluating the functional status of a patient&rsquo;s antibody response is measurement of existing titers of IgG antibodies to common pathogens. The pathogens examined are those to which the population is exposed through natural infection or vaccination. If baseline immunity is protective, then no further evaluation is indicated and the patient&rsquo;s antibody function is presumed to be normal. If baseline immunity is not protective, then further testing is warranted in the form of vaccine challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Protein antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus and diphtheria titers are measured to assess previous immune response to protein antigens. Most people received a series of vaccinations in childhood to protect against tetanus, diphtheria, and pertussis. This can be performed in all age groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link&amp;anchor=H12#H12\">",
"     \"Assessing the immunologic response to vaccination\", section on 'Assessing response to protein antigens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Polysaccharide antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous immune response to polysaccharide antigens can be assessed in children older than two years of age and in adults by measuring antibody titers to multiple serotypes of pneumococcus. Many people will have been exposed to Pneumococcus, either through natural infection or vaccination. These tests are commercially available, usually in panels of 12 to 23 serotypes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link&amp;anchor=H20#H20\">",
"     \"Assessing the immunologic response to vaccination\", section on 'Assessing polysaccharide responses in adults and children over two years'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a child under two years of age, it is not possible to assess a pure response to polysaccharide antigens because even children with normal immune systems often do not respond well to pure polysaccharide antigens at this age. However, it is our experience that young children who respond poorly to full immunization with conjugated pneumococcal vaccines often subsequently respond poorly to polysaccharide vaccines. As a result, the measurement of anti-pneumococcal and anti-Haemophilus influenzae B antibodies in children who have received conjugated vaccines for these pathogens is informative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link&amp;anchor=H18#H18\">",
"     \"Assessing the immunologic response to vaccination\", section on 'Assessing polysaccharide responses in children under two years'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vaccine challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine challenge refers to the administration of vaccines with analysis of pre- and post-immunization titers. It serves as a laboratory correlate of the patient's ability to respond effectively to natural infections, and is a means of determining the clinical significance of an IgG subclass deficiency. Lack of response, especially to pneumococcal and H. influenzae vaccines, correlates with susceptibility to recurrent sinopulmonary infections clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/7,13,19,26,29-31,55\">",
"     7,13,19,26,29-31,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interpretation of a patient's response to vaccine challenge is straightforward for the protein-based vaccines, tetanus and diphtheria. The response is considered adequate if the patient's levels are protective after vaccination (as defined by the laboratory performing the assay).",
"   </p>",
"   <p>",
"    The interpretation of a response to unconjugated pneumococcal vaccine is more involved because the normal response is influenced by the age of the patient. One recommended approach is the following [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children two to five years of age, a normal response consists of a post-immunization titer &ge;1.3",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (or the level considered protective by the performing laboratory) to at least 50 percent of the serotypes tested.",
"     </li>",
"     <li>",
"      In children &gt;5 years of age and in adults, a normal response consists of a post-immunization titer &ge;1.3",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (or the level considered protective by the performing laboratory) to at least 70 percent of the serotypes tested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of normal and abnormal responses to pneumococcal vaccines is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18031135\">",
"    <span class=\"h2\">",
"     Response patterns seen with IgG subclass deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine responses of patients with IgG subclass deficiencies are characterized by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with IgG1 subclass deficiency usually have hypogammaglobulinemia and are diagnosed with other disorders, as previously discussed. Vaccine response in these disorders is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"       \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=see_link\">",
"       \"Transient hypogammaglobulinemia of infancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with IgG2 subclass deficiency (possibly in combination with IgG4 deficiency) have defective polysaccharide vaccine responses with some regularity. By comparison, such patients typically have normal baseline immunity to protein antigens and respond normally to protein vaccines.",
"     </li>",
"     <li>",
"      Patients with isolated IgG3 deficiency usually display normal responses to protein antigens and normal or impaired responses to polysaccharide antigens. Patients with IgG3 deficiency in association with IgG1 deficiency can have poor responses to protein antigens, and often respond poorly to polysaccharide antigens as well.",
"     </li>",
"     <li>",
"      Patients with IgG4 deficiency typically produce normal antibody responses to both protein and polysaccharide antigens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Memory and switched B cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased memory (CD27+) and switched (IgM-IgD-CD27+) B cells have been described in CVID and selective antibody deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. These B cell subpopulations are also decreased in children with selective antibody deficiency associated with IgG2 subclass deficiency. The utility of assessing subpopulations of B cells is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link&amp;anchor=H2350217#H2350217\">",
"     \"Common variable immunodeficiency in children\", section on 'B cell studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions must be considered in patients with clinical features suggestive of IgG subclass deficiency but lacking either of the two criteria for the diagnosis, ie, low IgG subclass levels or poor response to vaccine challenge.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Selective antibody deficiency",
"      </strong>",
"      &mdash; Some patients with recurrent sinopulmonary infections have normal subclass levels and normal levels of IgG, IgA, and IgM but defective immune responses to vaccination. This disorder is referred to as selective antibody deficiency with normal immunoglobulins, or polysaccharide non-response. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=see_link\">",
"       \"Selective antibody deficiency with normal immunoglobulins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Functionally normal",
"      </strong>",
"      &mdash; Patients with low IgG subclass levels but normal immune responses to vaccination may be immunologically normal. Many such patients have been described. This combination of findings in a child may represent the evolution of transient hypogammaglobulinemia of infancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=see_link\">",
"       \"Transient hypogammaglobulinemia of infancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Secondary immunodeficiency",
"      </strong>",
"      &mdash; Patients with IgG subclass deficiency, normal immune responses to vaccination, and recurrent sinopulmonary infections may have secondary hypogammaglobulinemia. Secondary hypogammaglobulinemia can result from either decreased production or increased loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Malignancy (chronic lymphocytic leukemia or lymphoma) can result in decreased immunoglobulin production [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral infections, such as Epstein-Barr virus, HIV, cytomegalovirus, and congenital rubella and systemic illnesses causing bone marrow suppression are other secondary causes of hypogammaglobulinemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain medications, including systemic glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , and the anti-epileptics",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"       zonisamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , have been associated with acquired cases of IgG subclass deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/82-86\">",
"       82-86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"       \"Secondary immune deficiency induced by drugs and biologics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased loss of immunoglobulins can be observed in protein-losing enteropathies, nephrotic syndrome, burns, and other traumas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cigarette smoking has also been associated with lower IgG2 subclass levels [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with IgG subclass deficiencies do well with appropriate treatment and suffer significantly fewer sinopulmonary infections and disability. Treatment of patients with IgG subclass deficiency includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunization with conjugate vaccines in patients who have not responded to polysaccharide vaccines",
"     </li>",
"     <li>",
"      Aggressive management of other conditions predisposing to recurrent sinopulmonary infections (eg, asthma, allergic rhinitis)",
"     </li>",
"     <li>",
"      Increased vigilance and appropriate antibiotic therapy for infections",
"     </li>",
"     <li>",
"      Prophylactic antibiotics",
"     </li>",
"     <li>",
"      Intravenous or subcutaneous immunoglobulin replacement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once treatment is initiated, patients need to be monitored, as some individuals will progress to more severe immune disorders, such as CVID, while others may resolve. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with subclass deficiency and poor responses to polysaccharide vaccines should receive a conjugated pneumococcal vaccine, in order to boost immunity to this common respiratory pathogen. There are no data examining efficacy of these vaccines in patients with IgG subclass deficiency, although benefits have been observed in children with selective antibody deficiency with normal immunoglobulins (vaccine non-response). As an example, in one study of patients with vaccine non-response, the conjugated pneumococcal vaccine (Prevnar",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Wyeth-Ayerst or a similar preparation) produced a protective response in 80 to 90 percent of patients (greater than two years of age) who failed to respond to the polysaccharide vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/88\">",
"     88",
"    </a>",
"    ]. A similar response is presumed to occur in patients with subclass deficiency, as clinical improvement is often observed after this intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H3#H3\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Conjugate vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1918323\">",
"    <span class=\"h2\">",
"     Treatment of infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt recognition and treatment of sinopulmonary bacterial infections is a significant component of management of these patients, since infections are less likely to clear spontaneously in patients with antibody defects. When possible, infections should be verified through sinus and lung imaging, complete blood counts, measurement of C-reactive protein levels or the erythrocyte sedimentation rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=see_link\">",
"     \"Acute bronchitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Acute bacterial rhinosinusitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Management of other sinopulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive management of any conditions predisposing to recurrent sinopulmonary infections (especially allergic rhinitis and asthma) is critical to improving the clinical outcome of patients with IgG subclass deficiency. Atopic disorders occurred in 55 to 58 percent of the children with selective antibody deficiency with or without IgG2-IgA deficiency in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/55\">",
"     55",
"    </a>",
"    ]. A high percentage of patients in our practice have concurrent allergic disease, although the incidence of allergy in an unselected population is unknown.",
"   </p>",
"   <p>",
"    Management of allergic rhinitis and asthma includes allergy evaluation and trigger avoidance, nasal and inhaled glucocorticoids, bronchodilators, and antihistamines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with IgG subclass deficiencies appear to respond normally to allergen immunotherapy for allergic rhinitis and asthma and should receive this therapy when appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with recurrent sinopulmonary infections despite the previously described measures usually require prophylactic antibiotics. Evidence in support of this approach is largely derived from benefits observed in retrospective studies of children with this and similar antibody deficiencies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest studies examined 120 children aged 2 to 15 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/55\">",
"       55",
"      </a>",
"      ]. Seventy-two percent were successfully managed with prophylactic antibiotics. Those who did not respond subsequently required immunoglobulin replacement therapy.",
"     </li>",
"     <li>",
"      In another series of 59 children, prophylactic antibiotics were administered if the patient had more than six upper respiratory tract infections in one year, with or without an immunostimulant bacterial lysate, and immune globulin was administered to those who failed to improve adequately [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/12,89\">",
"       12,89",
"      </a>",
"      ]. During the years the children were followed, 90 percent required one of these therapies and 15 percent received immune globulin. In the treated group, the frequency of infections decreased from 13 &plusmn; 7 to 6 &plusmn; 4 per year [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our clinic, approximately one-half of patients require prophylactic antibiotics. The specific prophylactic antibiotic selected should cover the bacteria that most commonly cause sinopulmonary infections, such as S. pneumoniae (including penicillin resistant strains), non-typable H. influenzae, and M. catarrhalis.",
"   </p>",
"   <p>",
"    In children, we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose (maximum dose 875 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ) administered once per day or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"     cefdinir",
"    </a>",
"    7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose (maximum dose 300 mg) given once per day. Other experts recommend different regimens for antibiotic prophylaxis in patients with immunodeficiency and the choice of agent and dose should be based upon resistance patterns within a community. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Immune globulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Judicious use of immune globulin therapy is appropriate if the use of prophylactic antibiotics does not result in fewer infections,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in patients with persistent and symptomatic chronic rhinosinusitis. This therapy should be reserved for patients with clearly impaired responses to protein",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polysaccharide antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Most of the patients requiring this intervention have impaired antibody responses to bacterial polysaccharide antigens with IgG2",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    IgG4 deficiency. Intravenous immune globulin (IGIV) therapy, at a standard dose range of 400 to 600",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    can be infused every four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/92\">",
"     92",
"    </a>",
"    ]. Immune globulin can also be replaced subcutaneously at weekly intervals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with selective IgG4 or IgG3 deficiency usually have normal antibody responses, although differing degrees of impaired specific antibody responses in patients with IgG3 deficiency have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/59,93,94\">",
"     59,93,94",
"    </a>",
"    ]. The role of immune globulin in these patients is not as clear. However, several studies have reported clinical improvement in patients with IgG3 deficiency as a result of this intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/59,93,95,96\">",
"     59,93,95,96",
"    </a>",
"    ]. In the largest, which included 33 patients with IgG3 deficiency, patients with more than four antibiotic-requiring respiratory tract infections (RTIs) per year were treated with immune globulin and the number of RTIs before and during treatment was compared [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/96\">",
"     96",
"    </a>",
"    ]. Reduction in the number of RTIs was seen in 29 of 33 patients with IgG3 deficiency: 23 experienced a &gt;50 percent reduction, and 6 had a reduction of &lt;50 percent.",
"   </p>",
"   <p>",
"    Immune globulin therapy should be administered for one to two years initially, at which point the patient's status should be reevaluated to determine if the number",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of infections have been reduced. Not all patients with IgG subclass deficiencies benefit from Ig replacement and the therapy should be discontinued if not effective in that individual [",
"    <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of IgG subclass deficiency is influenced by the age of the patient as well as the degree of deficiency.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence suggests that the majority of children younger than six to eight years of age with clinically significant IgG subclass deficiency and diminished specific antibody responses will normalize both antibody responsiveness and IgG subclass level(s) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/2,55\">",
"       2,55",
"      </a>",
"      ]. This appears to be particularly true for young children with IgG2 and IgA deficiency and deficient responses to polysaccharide antigens. In contrast, if the condition persists beyond the age of six years, it is likely to be permanent.",
"     </li>",
"     <li>",
"      Adults with clinically significant IgG subclass deficiency and diminished specific antibody responses will rarely achieve normalization of a deficient IgG subclass level [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/2\">",
"       2",
"      </a>",
"      ]. A subset of these patients will progress to CVID. Development of chronic pulmonary disease, such as bronchiectasis, is also a risk for such patients and they must be monitored closely [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37978?source=see_link&amp;anchor=H23102184#H23102184\">",
"       \"Pulmonary complications of primary immunodeficiencies\", section on 'Monitoring for pulmonary disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spontaneous resolution is less likely to occur in cases of complete absence of an IgG subclass, regardless of age.",
"     </li>",
"     <li>",
"      The risk of lymphoma in patients with IgG subclass deficiencies has not been evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring is influenced by the patient's age and the severity of illness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In affected younger children (up to six years of age), levels of immunoglobulins and IgG subclasses should be measured yearly. Vaccine response should be assessed again if levels normalize.",
"     </li>",
"     <li>",
"      In symptomatic older children with persistent deficiency and in adults, we reevaluate levels annually for several years. If the condition persists throughout this period, then reassessment can be less frequent. However, periodic testing should continue to monitor for evolving common variable immunodeficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/60/13258/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients receiving immune globulin replacement therapy, treatment should periodically be held after one to two years for immunologic and clinical reassessment. When discontinuing immune globulin, it is advisable to do so during the spring months to minimize exposure to viral infections. We generally wait three or four months after discontinuation before performing immune testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"       \"General principles in the use of immune globulin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Up to 20 percent of the population has low levels of one or more of the IgG subclasses with normal levels of total serum IgG. Subclass deficiency is considered to be a clinically relevant immunodeficiency",
"      <strong>",
"       only",
"      </strong>",
"      if vaccine response is impaired and the patient suffers from recurrent infections. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with low levels of one or more IgG subclasses are asymptomatic. Those with symptomatic IgG subclass deficiencies typically suffer from repeated sinopulmonary infections. Osteomyelitis, meningitis, septicemia, diarrhea, and various skin infections are reported less often. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The different subclass deficiencies may have specific clinical characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      IgG1 deficiency almost always presents as hypogammaglobulinemia, since IgG1 normally makes up about 70 percent of total IgG. Selective IgG1 deficiency with normal total IgG is uncommon.",
"     </li>",
"     <li>",
"      IgG1 and IgG3 deficiency frequently occur together and are more common in adults. Infections with Moraxella catarrhalis and Streptococcus pyogenes are typical.",
"     </li>",
"     <li>",
"      IgG2 deficiency, which may occur in combination with IgG4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgA deficiency, is more common in children. Infections with Streptococcus pneumonia, Haemophilus influenzae type b (Hib), and Neisseria meningitides are characteristic, since IgG2 comprises most of the antibody response against polysaccharide capsular antigens.",
"     </li>",
"     <li>",
"      IgG4 deficiency is relatively common. Affected individuals may or may not be symptomatic with sinopulmonary infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial evaluation of patients suspected of having IgG subclass deficiency involves screening laboratory tests, including CBC and differential, total IgG, IgM, IgA levels and CH50. The diagnosis should be considered in a patient with a clinical history suggestive of a defect in humoral immunity whose screening laboratory tests are normal. In this situation, the patient's responses to past infections and vaccination are assessed, and IgG subclass levels are measured. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of a clinically significant IgG subclass deficiency involves fulfilling the following two components. (See",
"      <a class=\"local\" href=\"#H1701610\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One or more low IgG subclasses with normal or near normal total IgG. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Measurement techniques and normal levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inadequate response to vaccination. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Vaccine challenge'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management consists of immunization with conjugate vaccines in patients who have not responded to polysaccharide vaccines, aggressive treatment of other conditions predisposing to recurrent sinopulmonary infections (eg, asthma, allergic rhinitis), and increased vigilance and appropriate antibiotic therapy for infections. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of prophylactic antibiotics for patients with repeated sinopulmonary infections despite the above measures (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The choice of agent and dose should be based upon resistance patterns within a community. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend immune globulin therapy for patients with clearly impaired protein",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      polysaccharide vaccine responses, in whom the use of prophylactic antibiotics has not resulted in fewer infections (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Immune globulin therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/1\">",
"      Herrod HG. Clinical significance of IgG subclasses. Curr Opin Pediatr 1993; 5:696.",
"     </a>",
"    </li>",
"    <li>",
"     Ochs HD, Stiehm ER, Winkelstein JA, et al. Antibody deficiencies. In: Immunologic disorders in infants and children, 5th ed, Ochs HD, Stiehm ER, Winkelstein JA (Eds), Elsevier, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/3\">",
"      Hanson LA, S&ouml;derstr&ouml;m R, Avanzini A, et al. Immunoglobulin subclass deficiency. Pediatr Infect Dis J 1988; 7:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/4\">",
"      S&ouml;derstr&ouml;m T, S&ouml;derstr&ouml;m R, Avanzini A, et al. Immunoglobulin G subclass deficiencies. Int Arch Allergy Appl Immunol 1987; 82:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/5\">",
"      Oxelius VA, Hanson LA, Bj&ouml;rkander J, et al. IgG3 deficiency: common in obstructive lung disease. Hereditary in families with immunodeficiency and autoimmune disease. Monogr Allergy 1986; 20:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/6\">",
"      Aucouturier P, Lacombe C, Bremard C, et al. Serum IgG subclass levels in patients with primary immunodeficiency syndromes or abnormal susceptibility to infections. Clin Immunol Immunopathol 1989; 51:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/7\">",
"      Bj&ouml;rkander J, Bengtsson U, Oxelius VA, Hanson LA. Symptoms in patients with lowered levels of IgG subclasses, with or without IgA deficiency, and effects of immunoglobulin prophylaxis. Monogr Allergy 1986; 20:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/8\">",
"      Migone N, Oliviero S, de Lange G, et al. Multiple gene deletions within the human immunoglobulin heavy-chain cluster. Proc Natl Acad Sci U S A 1984; 81:5811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/9\">",
"      Nahm MH, Macke K, Kwon OH, et al. Immunologic and clinical status of blood donors with subnormal levels of IgG2. J Allergy Clin Immunol 1990; 85:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/10\">",
"      Aucouturier P, Mariault M, Lacombe C, Preud'homme JL. Frequency of selective IgG subclass deficiency: a reappraisal. Clin Immunol Immunopathol 1992; 63:289.",
"     </a>",
"    </li>",
"    <li>",
"     Meulenbroek AJ, Zeijlemaker WP. Human IgG subclasses: Useful diagnostic markers for immunocompetence, 2nd edition, CLB, Amsterdam, The Netherlands 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/12\">",
"      Karaca NE, Karadeniz C, Aksu G, Kutukculer N. Clinical and laboratory evaluation of periodically monitored Turkish children with IgG subclass deficiencies. Asian Pac J Allergy Immunol 2009; 27:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/13\">",
"      Schur PH, Borel H, Gelfand EW, et al. Selective gamma-g globulin deficiencies in patients with recurrent pyogenic infections. N Engl J Med 1970; 283:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/14\">",
"      Shackelford PG, Granoff DM, Madassery JV, et al. Clinical and immunologic characteristics of healthy children with subnormal serum concentrations of IgG2. Pediatr Res 1990; 27:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/15\">",
"      Oxelius VA. Chronic infections in a family with hereditary deficiency of IgG2 and IgG4. Clin Exp Immunol 1974; 17:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/16\">",
"      Lefranc MP, Lefranc G, Rabbitts TH. Inherited deletion of immunoglobulin heavy chain constant region genes in normal human individuals. Nature 1982; 300:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/17\">",
"      Hammarstr&ouml;m L, Smith CI. IgG2 deficiency in a healthy blood donor. Concomitant lack of IgG2, IgA and IgE immunoglobulins and specific anti-carbohydrate antibodies. Clin Exp Immunol 1983; 51:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/18\">",
"      Morgan G, Levinsky RJ. Clinical significance of IgG subclass deficiency. Arch Dis Child 1988; 63:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/19\">",
"      Umetsu DT, Ambrosino DM, Quinti I, et al. Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency. N Engl J Med 1985; 313:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/20\">",
"      Lawton AR. IgG subclass deficiency and the day-care generation. Pediatr Infect Dis J 1999; 18:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/21\">",
"      Hill SL, Mitchell JL, Burnett D, Stockley RA. IgG subclasses in the serum and sputum from patients with bronchiectasis. Thorax 1998; 53:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/22\">",
"      Lefranc MP, Hammarstr&ouml;m L, Smith CI, Lefranc G. Gene deletions in the human immunoglobulin heavy chain constant region locus: molecular and immunological analysis. Immunodefic Rev 1991; 2:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/23\">",
"      Hammarstr&ouml;m L, Carbonara AO, DeMarchi M, et al. Generation of the antibody repertoire in individuals with multiple immunoglobulin heavy chain constant region gene deletions. Scand J Immunol 1987; 25:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/24\">",
"      Plebani A, Ugazio AG, Meini A, et al. Extensive deletion of immunoglobulin heavy chain constant region genes in the absence of recurrent infections: when is IgG subclass deficiency clinically relevant? Clin Immunol Immunopathol 1993; 68:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/25\">",
"      Depiero A, Kaminski DA, Halsey JF, et al. Immunologic compensation in a patient with a large IgH constant region deletion. J Allergy Clin Immunol 2001; 107:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/26\">",
"      Ambrosino DM, Umetsu DT, Siber GR, et al. Selective defect in the antibody response to Haemophilus influenzae type b in children with recurrent infections and normal serum IgG subclass levels. J Allergy Clin Immunol 1988; 81:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/27\">",
"      Lacombe C, Aucouturier P, Preud'homme JL. Selective IgG1 deficiency. Clin Immunol Immunopathol 1997; 84:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/28\">",
"      Javier FC 3rd, Moore CM, Sorensen RU. Distribution of primary immunodeficiency diseases diagnosed in a pediatric tertiary hospital. Ann Allergy Asthma Immunol 2000; 84:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/29\">",
"      Oxelius VA, Laurell AB, Lindquist B, et al. IgG subclasses in selective IgA deficiency: importance of IgG2-IgA deficiency. N Engl J Med 1981; 304:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/30\">",
"      Braconier JH, Nilsson B, Oxelius VA, Karup-Pedersen F. Recurrent pneumococcal infections in a patient with lack of specific IgG and IgM pneumococcal antibodies and deficiency of serum IgA, IgG2 and IgG4. Scand J Infect Dis 1984; 16:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/31\">",
"      Siber GR, Schur PH, Aisenberg AC, et al. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 1980; 303:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/32\">",
"      Hammarstr&ouml;m L, Smith CI. IgG subclasses in bacterial infections. Monogr Allergy 1986; 19:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/33\">",
"      Bass JL, Nuss R, Mehta KA, et al. Recurrent meningococcemia associated with IgG2-subclass deficiency. N Engl J Med 1983; 309:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/34\">",
"      Escobar-P&eacute;rez X, Dorta-Contreras AJ, Interi&aacute;n-Morales MT, et al. IgG2 immunodeficiency: association to pediatric patients with bacterial meningoencephalitis. Arq Neuropsiquiatr 2000; 58:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/35\">",
"      O'Keeffe S, Finnegan P. IgG subclass deficiency. Chest 1993; 104:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/36\">",
"      Bussel J, Morell A, Skvaril F. IgG2 deficiency in autoimmune cytopenias. Monogr Allergy 1986; 20:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/37\">",
"      Oxelius VA. Immunoglobulin G (IgG) subclasses and human disease. Am J Med 1984; 76:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/38\">",
"      Eriksson P, Almroth G, Denneberg T, Lindstr&ouml;m FD. IgG2 deficiency in primary Sj&ouml;gren's syndrome and hypergammaglobulinemic purpura. Clin Immunol Immunopathol 1994; 70:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/39\">",
"      Jim&eacute;nez A, L&oacute;pez-Trascasa M, Font&aacute;n G. Incidence of selective IgG2 deficiency in patients with vasculitis. Clin Exp Immunol 1989; 78:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/40\">",
"      Inoue R, Kondo N, Kobayashi Y, et al. IgG2 deficiency associated with defects in production of interferon-gamma; comparison with common variable immunodeficiency. Scand J Immunol 1995; 41:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/41\">",
"      Oxelius VA, Berkel AI, Hanson LA. IgG2 deficiency in ataxia-telangiectasia. N Engl J Med 1982; 306:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/42\">",
"      Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency. Ann Allergy Asthma Immunol 2003; 90:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/43\">",
"      Lotz DR, Knutsen AP. Concomitant selective antibody deficiency in pediatric patients with mannose-binding lectin deficiency. Pediatric Allergy, Immunology, and Pulmonology 2010; 23:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/44\">",
"      Parkin JM, Helbert M, Hughes CL, Pinching AJ. Immunoglobulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS. AIDS 1989; 3:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/45\">",
"      Aucouturier P, Barra A, Intrator L, et al. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood 1987; 70:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/46\">",
"      Chan JF, To KK, Tse H, et al. The lower serum immunoglobulin G2 level in severe cases than in mild cases of pandemic H1N1 2009 influenza is associated with cytokine dysregulation. Clin Vaccine Immunol 2011; 18:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/47\">",
"      Zenone T, Souquet PJ, Cunningham-Rundles C, Bernard JP. Hodgkin's disease associated with IgA and IgG subclass deficiency. J Intern Med 1996; 240:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/48\">",
"      Garside JP, Kerrin DP, Brownlee KG, et al. Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic. Pediatr Pulmonol 2005; 39:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/49\">",
"      De Gracia J, Rodrigo MJ, Morell F, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med 1996; 153:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/50\">",
"      Wilson NW, Daaboul J, Bastian JF. Association of autoimmunity with IgG2 and IgG4 subclass deficiency in a growth hormone-deficient child. J Clin Immunol 1990; 10:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/51\">",
"      Ojuawo A, Milla PJ, Lindley KJ. Serum immunoglobulin and immunoglobulin G subclasses in children with allergic colitis. West Afr J Med 1998; 17:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/52\">",
"      Caksen H, Oner AF, Arslan S, et al. Immunoglobulin subgroups in children with febrile seizures. Pediatr Int 2001; 43:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/53\">",
"      Lenti C, Masserini C, Barlocco A, et al. IgG2 deficiency in children with febrile convulsions: a familial study. Ital J Neurol Sci 1993; 14:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/54\">",
"      Knutsen AP, Becker BA. Evolution of IgG subclass deficiency into common variable immunodeficiency in a child with pulmonary interstitial glycogenosis. Pediatr Asthma Allergy Immunol 2009; 21:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/55\">",
"      Wolpert J, Knutsen AP. Natural history of selective antibody deficiency to bacterial polysaccharide antigens in children. Pediatr Asthma Allergy Immunol 1998; 12:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/56\">",
"      Oxelius VA. Serum IgG and IgG subclass contents in different Gm phenotypes. Scand J Immunol 1993; 37:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/57\">",
"      Oxelius VA. IgG subclass pattern in primary immunodeficiency disorders. Monogr Allergy 1986; 19:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/58\">",
"      de Moraes Lui C, Oliveira LC, Diogo CL, et al. Immunoglobulin G subclass concentrations and infections in children and adolescents with severe asthma. Pediatr Allergy Immunol 2002; 13:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/59\">",
"      Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol 2010; 159:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/60\">",
"      Snowden JA, Milford-Ward A, Cookson LJ, McKendrick MW. Recurrent lymphocytic meningitis associated with hereditary isolated IgG subclass 3 deficiency. J Infect 1993; 27:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/61\">",
"      Heiner DC, Myers A, Beck CS. Deficiency of IgG4: a disorder associated with frequent infections and bronchiectasis that may be familial. Clin Rev Allergy 1983; 1:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/62\">",
"      Bartmann P, Kleihauer E. Undetectable IgG4 in immunoprecipitation: association with repeated infections in children? Eur J Pediatr 1988; 148:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/63\">",
"      Moss RB, Carmack MA, Esrig S. Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection. J Pediatr 1992; 120:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/64\">",
"      Anner&eacute;n G, Magnusson CG, Lilja G, Nordvall SL. Abnormal serum IgG subclass pattern in children with Down's syndrome. Arch Dis Child 1992; 67:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/65\">",
"      Yount WJ, Seligmann M, Hong R, et al. Imbalances of gamma globulin subgroups and gene defects in patients with primary hypogammaglobulinemia. J Clin Invest 1970; 49:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/66\">",
"      Plebani A, Monafo V, Avanzini MA, et al. Relationship between IgA and IgG subclass deficiencies: a reappraisal. Monogr Allergy 1986; 20:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/67\">",
"      Bremard-Oury C, Aucouturier P, Debr&eacute; M, et al. Immunoglobulin G subclasses in patients with immunodeficiencies. Monogr Allergy 1986; 20:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/68\">",
"      Duse M, Tiberti S, Plebani A, et al. IgG2 deficiency and intractable epilepsy of childhood. Monogr Allergy 1986; 20:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/69\">",
"      Rabbani H, Kondo N, Smith CI, Hammarstr&ouml;m L. The influence of gene deletions and duplications within the IGHC locus on serum immunoglobulin subclass levels. Clin Immunol Immunopathol 1995; 76:S214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/70\">",
"      Pan Q, Hammarstr&ouml;m L. Molecular basis of IgG subclass deficiency. Immunol Rev 2000; 178:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/71\">",
"      Plebani A, Carbonara AO, Bottaro A, et al. Gene deletion as a cause of associated deficiency of IgA1, IgG2, IgG4 and IgE. Immunodeficiency 1993; 4:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/72\">",
"      Carbonara AO, Demarchi M. Ig isotypes deficiency caused by gene deletions. Monogr Allergy 1986; 20:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/73\">",
"      Bottaro A, DeMarchi M, DeLange GG, et al. Human IGHC locus restriction fragment length polymorphisms in IgG4 deficiency: evidence for a structural IGHC defect. Eur J Immunol 1989; 19:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/74\">",
"      Kondo N, Inoue R, Kasahara K, et al. Reduced expression of the interferon-gamma messenger RNA in IgG2 deficiency. Scand J Immunol 1997; 45:227.",
"     </a>",
"    </li>",
"    <li>",
"     Abbas AK, Lichtman AH. B cell activation and antibody production. In: Cellular and molecular immunology, 5th ed, Abbas AK, Lichtman AH (Eds), Saunders, Philadelphia 2003. p.189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/76\">",
"      Oxelius VA. Lack of the G2m(n) allotype in IgG subclass deficiency, in IgG2 deficiency together with lack of G1m(a) and G3m(g), and in IgG3 deficiency together with lack of G1m(f) and G3m(b). Scand J Immunol 1990; 31:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/77\">",
"      Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/78\">",
"      Hamilton RG. Human IgG subclass measurements in the clinical laboratory. Clin Chem 1987; 33:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/79\">",
"      Bossuyt X, Mari&euml;n G, Meyts I, et al. Determination of IgG subclasses: a need for standardization. J Allergy Clin Immunol 2005; 115:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/80\">",
"      Ko J, Radigan L, Cunningham-Rundles C. Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immunol 2005; 116:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/81\">",
"      Alachkar H, Taubenheim N, Haeney MR, et al. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol 2006; 120:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/82\">",
"      Klaustermeyer WB, Gianos ME, Kurohara ML, et al. IgG subclass deficiency associated with corticosteroids in obstructive lung disease. Chest 1992; 102:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/83\">",
"      Leickly FE, Buckley RH. Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy. J Pediatr 1986; 108:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/84\">",
"      Maeoka Y, Hara T, Dejima S, Takeshita K. IgA and IgG2 deficiency associated with zonisamide therapy: a case report. Epilepsia 1997; 38:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/85\">",
"      Ishizaka A, Nakanishi M, Kasahara E, et al. Phenytoin-induced IgG2 and IgG4 deficiencies in a patient with epilepsy. Acta Paediatr 1992; 81:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/86\">",
"      Kato Z, Watanabe M, Kondo N. IgG2, IgG4 and IgA deficiency possibly associated with carbamazepine treatment. Eur J Pediatr 2003; 162:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/87\">",
"      Qvarfordt I, Riise GC, Andersson BA, Larsson S. IgG subclasses in smokers with chronic bronchitis and recurrent exacerbations. Thorax 2001; 56:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/88\">",
"      Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998; 17:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/89\">",
"      Guti&eacute;rrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest 2001; 119:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/90\">",
"      Buckley RH. Immunoglobulin G subclass deficiency: fact or fancy? Curr Allergy Asthma Rep 2002; 2:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/91\">",
"      Abdou NI, Greenwell CA, Mehta R, et al. Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults. Int Arch Allergy Immunol 2009; 149:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/92\">",
"      Shearer WT, Buckley RH, Engler RJ, et al. Practice parameters for the diagnosis and management of immunodeficiency. The Clinical and Laboratory Immunology Committee of the American Academy of Allergy, Asthma, and Immunology (CLIC-AAAAI). Ann Allergy Asthma Immunol 1996; 76:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/93\">",
"      Meyts I, Bossuyt X, Proesmans M, De B. Isolated IgG3 deficiency in children: to treat or not to treat? Case presentation and review of the literature. Pediatr Allergy Immunol 2006; 17:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/94\">",
"      Avanzini MA, Bj&ouml;rkander J, S&ouml;derstr&ouml;m R, et al. Qualitative and quantitative analyses of the antibody response elicited by Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in adults with IgG subclass deficiencies and frequent infections. Clin Exp Immunol 1994; 96:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/95\">",
"      Barlan IB, Geha RS, Schneider LC. Therapy for patients with recurrent infections and low serum IgG3 levels. J Allergy Clin Immunol 1993; 92:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/60/13258/abstract/96\">",
"      Olinder-Nielsen AM, Granert C, Forsberg P, et al. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scand J Infect Dis 2007; 39:44.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3906 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13258=[""].join("\n");
var outline_f12_60_13258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6410636\">",
"      Asymptomatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6410643\">",
"      Symptomatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - IgG1 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - IgG2 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - IgG3 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - IgG4 deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22337729\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3396155\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1701973\">",
"      Initial laboratories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1701937\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1701610\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Measurement techniques and normal levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Assessing function of IgG subclasses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18031031\">",
"      - Measure baseline immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Protein antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Polysaccharide antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vaccine challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18031135\">",
"      Response patterns seen with IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Memory and switched B cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1918323\">",
"      Treatment of infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Management of other sinopulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Immune globulin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3906\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3906|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/0/30734\" title=\"figure 1\">",
"      Normal IgG subclass levels in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3906|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/61/40923\" title=\"table 1\">",
"      Low IgG subclass levels in different populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/48/6925\" title=\"table 2\">",
"      Levels of IgG subclasses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=related_link\">",
"      Acute bronchitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=related_link\">",
"      Approach to the adult with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=related_link\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=related_link\">",
"      IgG subclasses: Physical properties, genetics, and biologic functions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=related_link\">",
"      Mannose-binding lectin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37978?source=related_link\">",
"      Pulmonary complications of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=related_link\">",
"      Transient hypogammaglobulinemia of infancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_60_13259="ASGE guideline personnel propaf";
var content_f12_60_13259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Appropriate personnel and equipment for propofol use in an endoscopic procedure room",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        At least one person who is qualified in both basic and advanced life support skills (ie, tracheal intubation, defibrillation, use of resuscitation medications)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physiologic monitoring should include pulse oximetry, electrocardiography, and automated blood pressure measurement. Monitoring oxygenation by pulse oximetry is not a substitute for monitoring ventilatory function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Equipment for airway management and resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trained personnel dedicated to the continuous and uninterrupted monitoring of the patient's physiologic parameters and administration of propofol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extended monitoring with capnography should be considered as it may decrease the risks during deep sedation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Faigel DO, Baron TH, Goldstein JL, et al. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc 2002; 56:613. Copyright &copy; 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13259=[""].join("\n");
var outline_f12_60_13259=null;
var title_f12_60_13260="CAM professionals";
var content_f12_60_13260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    State licensure of CAM professionals and information resources for state licensing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Licensed in 10 or more states",
"       </td>",
"       <td class=\"subtitle1\">",
"        Information resource",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Licensed acupuncturist (LiAc)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        National Certification Commission for Acupuncture and Oriental Medicine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        904-598-1005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <a href=\"file://www.nccaom.org\" target=\"_blank\">",
"         www.nccaom.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        American Academy of Medical Acupuncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        310-364-0193",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <a href=\"file://www.medicalacupuncture.org\" target=\"_blank\">",
"         www.medicalacupuncture.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Doctors of chiropractic (DC)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Federation of Chiropractic Licensing Boards",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        970-356-3500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <a href=\"file://www.fclb.org\" target=\"_blank\">",
"         www.fclb.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Naturopathic doctor (NDs)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        American Association of Naturopathic Physicians",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        202-237-8150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        <a href=\"file://www.naturopathic.org\" target=\"_blank\">",
"         www.naturopathic.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Licensed massage therapist (LMT)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        National Certification Board for Therapeutic Massage and Bodywork",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        800-296-0664",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <a href=\"file://www.ncbtmb.com\" target=\"_blank\">",
"         www.ncbtmb.com",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Eisenberg DM. Ann Intern Med 1997: 127:61.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13260=[""].join("\n");
var outline_f12_60_13260=null;
var title_f12_60_13261="Esophagectomysuperf esoph CA";
var content_f12_60_13261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Esophagectomy outcomes in superficial esophageal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year (accrual time)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mortality rate, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Survival (5-yr), percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recurrence rate, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Fujita H; 2001",
"        </p>",
"        <p>",
"         (1981-1997)",
"        </p>",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        Squam",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        <p>",
"         71 M",
"        </p>",
"        <p>",
"         74 SM-Rad",
"        </p>",
"        <p>",
"         31 SM-Std",
"        </p>",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Endo M; 2001",
"        </p>",
"        <p>",
"         (1985-1997)",
"        </p>",
"       </td>",
"       <td>",
"        236",
"       </td>",
"       <td>",
"        Squam",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Rice T; 2001",
"        </p>",
"        <p>",
"         (1985-1999)",
"        </p>",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        Adeno",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Liu L; 2005",
"        </p>",
"        <p>",
"         (1988-2003)",
"        </p>",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        Adeno",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        <p>",
"         91 M",
"        </p>",
"        <p>",
"         58 SM",
"        </p>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Westerterp M; 2005",
"        </p>",
"        <p>",
"         (1980-1993)",
"        </p>",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        Adeno",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Wang G; 2004",
"        </p>",
"        <p>",
"         (1972-2003)",
"        </p>",
"       </td>",
"       <td>",
"        420",
"       </td>",
"       <td>",
"        Squam",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Altorki N; 2008",
"        </p>",
"        <p>",
"         (1994-2006)",
"        </p>",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        <p>",
"         Squam (15)",
"        </p>",
"        <p>",
"         Adeno (60)",
"        </p>",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        78 (87*)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Pennathur A; 2009",
"        </p>",
"        <p>",
"         (1995-2004)",
"        </p>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <p>",
"         Squam (9)",
"        </p>",
"        <p>",
"         Adeno (91)",
"        </p>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        <p>",
"         73 (T1a)",
"        </p>",
"        <p>",
"         60 (T1b)",
"        </p>",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Barbour A; 2010",
"        </p>",
"        <p>",
"         (1991-2008)",
"        </p>",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        Adeno",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        <p>",
"         97 (T1a)",
"        </p>",
"        <p>",
"         70 SM1",
"        </p>",
"        <p>",
"         60 SM2",
"        </p>",
"        <p>",
"         71 SM3",
"        </p>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Tanaka T; 2012",
"        </p>",
"        <p>",
"         (1990-2008)&nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;105",
"       </td>",
"       <td>",
"        <p>",
"         Squam (98)",
"        </p>",
"        <p>",
"         Adeno (7)",
"        </p>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Squam: squamous carcinoma; Adeno: adenocarcinoma; NR: not reported; M: mucosal; SM: submucosal; Rad: radical en-bloc esophagectomy; Std: standard esophagectomy.",
"     <br>",
"      * Disease specific survival.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13261=[""].join("\n");
var outline_f12_60_13261=null;
var title_f12_60_13262="Methadone dose calculation";
var content_f12_60_13262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Methadone dose calculation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 380px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13262=[""].join("\n");
var outline_f12_60_13262=null;
var title_f12_60_13263="Main pancreatic duct stricture";
var content_f12_60_13263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic duct stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pancreatogram shows a dominant stricture (arrow) in the head of the pancreas following pancreatic duct stenting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Catalano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_60_13263=[""].join("\n");
var outline_f12_60_13263=null;
            